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ABSTRACT 
Duchenne muscular dystrophy (DMD) is caused by a mutation in the dystrophin gene 
leading to the production of a nonfunctional protein and a dystrophin deficiency.  Dystrophic 
muscle becomes progressively more necrotic and fibrotic eventually causing impaired muscle 
function.  Patients are typically diagnosed due to the loss of muscle function indicating 
advanced disease, therefore successful treatments need to be able to rescue dystrophin-
deficient muscle from further decline.  It has been demonstrated that Peroxisome proliferator-
activated receptor γ coactivator 1α (PGC-1α) over-expression can prevent disease onset in 
mdx mice, a mouse model for DMD.  As a next step, the work presented here evaluated the 
extent to which PGC-1α over-expression rescued dystrophic muscle during the initial bout of 
necrosis (three weeks of age) as well as after prolonged disease progression (one year of 
age).  AAV6 was used to deliver the PGC-1α gene to a single hind limb while the 
contralateral limb was given a control injection. PGC-1α gene transfer improved muscle 
function and histopathology when delivered during the initial bout of necrosis.  Also, 
beneficial changes in genes involved in dystroglycoprotein complex (DGC) assembly, 
oxidative metabolism, muscle repair, and autophagy were observed.  While PGC-1α gene 
transfer following prolonged disease rescued some aspects of muscle function the cumulative 
effects were more modest.  To increase the clinical relevance of this work the orally-
available PGC-1α pathway activator quercetin was evaluated for its ability to mitigate 
histopathology in dystrophic skeletal muscle. Using a rescue paradigm prolonged quercetin 
supplementation led to improved histopathology and increased mitochondrial biogenesis 
compared to control-fed animals. 
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Because of a variety of differences between animal models and human patients their 
usefulness as translational models is limited.  To that end dystrophin insufficient pigs were 
evaluated as a novel translational model.  At eight weeks of age dystrophin insufficiency 
resulted in failure of the DGC to localize to the sarcolemma. This was associated with 
increased histopathology in a muscle-specific manner. Since pigs are closer in size, 
physiology, anatomy and genetics to humans and also appear to recapitulate many aspects of 
dystrophinopathies we believe they will make for a good translational animal model for 
future therapeutic studies. 
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CHAPTER 1.  INTRODUCTION 
 
Duchenne muscular dystrophy (DMD) is the most common, fatal X-linked disease 
worldwide and affects 1:3,500 live boys born.  DMD leads to progressive muscle damage, 
wheelchair confinement and death due to respiratory or cardiac failure in the third decade 
(Eagle et al., 2002, Emery, 2002).  Patients are typically diagnosed in preschool-years, after 
the child shows impairments in motor function.  DMD is caused by a mutation in the 
dystrophin gene resulting in the production of a nonfunctional dystrophin protein.   
The generally milder Becker muscular dystrophy (BMD) is caused by lower levels of 
full length dystrophin protein or by expression of an altered dystrophin protein, usually the 
result of a truncation.  There is a wide range of disease severity including patients with 
almost no motor impairment to those patients that show impairments similar to that of DMD 
patients.  Since 60% of disease causing mutations are deletions Monaco et al. (Monaco et al., 
1988) proposed the reading frame theory, which postulates deletions that do not alter the 
reading frame will result in BMD whereas mutations that alter the reading frame will result 
in DMD.  Later, the same group found that the reading frame theory is true 92% of the time, 
however exceptions exist if the deletion is located in the cysteine rich region or the C-
terminal region it will likely cause DMD independent of reading frame (Koenig et al., 1989).   
 
Dystrophin gene 
 The dystrophin gene is 2.5 mega bases in length and contains 79 exons making it one 
of the largest genes in the human genome (Roberts et al., 1993).  To transcribe one 
dystrophin transcript takes over 16 hours (Tennyson et al., 1995).  Its size could be one of the 
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reasons for the high occurrence of de novo mutations.  Indeed, 1:3 mutations are without a 
family history of DMD.  Full length dystrophin is expressed primarily in muscle explaining 
the severe muscle pathology involved in DMD.  The dystrophin gene has three different 
promoters that can lead to a full length dystrophin transcript which are used in a tissue 
specific manner: muscle, brain, and purkinje fibers (Muntoni et al., 2003).  The transcript 
resulting from the three promoters differ only in the first exon.  The dystrophin gene also has 
at least four internal promoters, each of them using a unique first exon being spliced to exon 
35, 45, 56 or 63 when counted on the full length dystrophin.  Further, many more isoforms 
can be generated by alternative splicing, skipping exons and/ or rearranging exons (Byers et 
al., 1993, Boyce et al., 1991, Feener et al., 1989, D'Souza et al., 1995). In addition to disease-
related muscle damage the effects of mutations in the full length and small isoforms can be 
seen in the brain.  Not only is full length dystrophin transcript expressed in the brain, using 
the brain promoter, but so are shorter isoforms starting with a unique first exon followed by 
exon 45 or exon 63.  Mutations in dystrophin gene that alter the shorter brain expressed 
isoforms (second half of the DMD gene) correlate with cognitive impairment in DMD 
patients (Taylor et al., 2010).   
 
Dystrophin protein 
The full length product of the dystrophin gene from the muscle specific promoter is 
the 427 kDa dystrophin protein.  The dystrophin protein consists of four distinct regions: the 
N-terminal domain (exons 1-8) , central rod domain (exons 8-61 exon), cysteine-rich domain 
(exons 63-69 exon) , and the C-terminal domain (exons 70-79 exon) (Koenig et al., 1988) 
and each domain has its own functional role.  The N-terminal domain is the binding site for 
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cytoskeletal F-actin (Corrado et al., 1994).  The rod domain is postulated to give some 
flexibility to the protein through 24 spectrin-like repeats and four hinge regions (Koenig and 
Kunkel, 1990, Cross et al., 1990).  There is also an F-actin binding site in the rod-domain that 
is necessary for proper dystrophin function (Rybakova et al., 1996, Amann et al., 1998) and 
more recently it has been established that the rod domain (spectrin-like repeats 16 and 17) 
facilitate nNOS localization to the sarcolemma (Lai et al., 2013, Lai et al., 2009).  The 
cysteine-rich domain consists of a WW module (Bork and Sudol, 1994), an EF-hand like 
module (Koenig et al., 1988), and a ZZ module (Ponting et al., 1996).  All modules of the 
cysteine-rich domain participate in the interaction of dystrophin with β-dystroglycan 
(Ishikawa-Sakurai et al., 2004).  The C-terminal coiled-coiled motif also facilitates protein-
protein interactions between dystrophin and α-dystrobrevin and syntrophin (Blake et al., 
1995, Sadoulet-Puccio et al., 1997).   
 
Dystroglycoprotein complex 
Through these linkages dystrophin anchors the dystroglycoprotein complex (DGC), 
which serves to connect the intracellular environment with the extracellular environment 
(Ervasti and Campbell, 1993).  This link allows for lateral force transmission from the inside 
of the muscle cell to the extracellular matrix during muscle contractions.  The DGC consists 
of multiple proteins including cytosolic transmembrane and extracellular proteins that can be 
purified together (Ohlendieck et al., 1991, Ervasti et al., 1990).  Without functional 
dystrophin protein, as in DMD, the DGC will not assemble (Ervasti et al., 1990) leading to 
the loss of its signaling function and to inadequate force transduction.  Demonstrating the 
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importance of the DGC in normal muscle function is that mutation in multiple components of 
the DGC lead to a variety of limb-girdle muscular dystrophies.   
The DGC is composed of dysroglycans, a sarcoglycan complex, sarcospan, 
dystrobrevins and syntrophin.  Dystroglycan α and β are encoded by the same gene, and 
proteolytic cleavage of the protein precursor results in the two different protein isoforms.  α-
dystroglycan becomes highly glycosylated (Ibraghimovbeskrovnaya et al., 1992) and binds to 
laminin in the extra cellular matrix (Ervasti and Campbell, 1993).  The transmembrane 
protein β-dystroglycan interacts with dystrophin and α-dystroglycan as well as several 
signaling molecules.  Sarcoglycans are single pass transmembrane proteins that become 
glycosylated on the extracellular side.  The sarcoglycan complex consists of α, β, γ and δ -
sarcoglycan isoform (Roberds et al., 1993).  Through interaction with the dystroglycans they 
stabilize the DGC.  Also, sarcoglycans may be involved in signaling cascades (Ozawa et al., 
2005).  A mutation in any one of the sarcoglycans leads to limb-girdle muscular dystrophy.  
Sarcospan connects the DGC to the integrens, which also are able to aid in force transduction 
during muscle contraction.  This connection seems to stabilize the DGC (Marshall and 
Crosbie-Watson, 2013).  α-dystrobrevin has signaling rolls by assisting in localization of 
nNOS together with dystrophin and syntrophin but also is involved is stabilizing normal 
muscle architecture by interacting with intermediate filaments (Nakamori and Takahashi, 
2011).  Syntrophin interacts with multiple signaling proteins assembling a signalplex, 
including G-protein coupled receptors, iron channels and nNOS (Constantin, 2014). 
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Animal models 
Spontaneous DMD mutations are not only observed in humans but also other animals 
including dogs, cats and mice. These animals can be used in studies as model organism for 
DMD.  The mdx mouse was discovered due to elevated creatine kinase (Ck) levels in 1984 
(Bulfield et al., 1984).  Later the molecular basis for the phenotype was identified to be a 
point mutation in exon 23, which leads to a premature stop codon (Sicinski et al., 1989).  
Even though full length dystrophin is absent in mdx mice they generally suffer a far milder 
phenotype than typical DMD patients, increased utrophin abundance has been implicated in 
the mild phenotype of mdx mice (Law et al., 1994).  There is generally no fatty infiltration 
into muscle, the lifespan is only moderately reduced (~20%), and mdx mice do not have 
impaired mobility (Chamberlain et al., 2007).  The initial bout of necrosis starts at three 
weeks in the hind limbs muscle of mdx mice.  This phase of acute degeneration/regeneration 
persists from four- eight weeks (McGeachie et al., 1993, Tanabe et al., 1986).  During this 
time the mdx hind limb muscles recapitulate many aspects of the human pathology including 
localized necrosis and increased fiber size variability.  After eight weeks of age the 
degenerative fibers in the mdx hind limb muscle are much reduced until approximately one 
year of age (Pastoret and Sebille, 1995).  On the other hand, the diaphragm suffers a steady 
disease progression like is observed in human patients (Stedman et al., 1991).  In addition to 
the original mdx mouse, mice with different mutations in the dystrophin gene have been 
created by N-ethyl-nitrosourea (Chapman et al., 1989) or by targeted deletion of larger parts 
of the dystrophin gene (Kudoh et al., 2005, Araki et al., 1997).  Their pathology is similar to 
mdx mice but have not been studied as exhaustively.   
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In order to achieve a phenotype that would more closely resemble the phenotype 
observed in patients multiple double-knockout mouse models have been generated.  Because 
of higher utrophin expression in mdx mice compared to DMD patients mdx/utr
-/-
 mice have 
been generated, which express neither dystrophin nor utrophin (Deconinck et al., 1997, 
Grady et al., 1997).  Indeed, those mice have a much exacerbated phenotype including 
reduction in life span, impaired mobility, increased fibrosis and severe kyphosis.  Also their 
life span is rather short with mice dying as early as four weeks, making it difficult to have 
longer term studies.  The haploinsufficient utrophin mdx mouse (mdx/utr -/+) combines the 
benefits of both the mdx mouse and the mdx/utr -/- mouse.  The mdx/utr -/+ mouse has a 
more severe histopathology and muscle function compared to the mdx mouse.  However 
unlike the mdx/urt-/- mouse their life span is longer, over one year, and there are no breading 
difficulties associated with the genotype (Zhou et al., 2008, van Putten et al., 2012).  The 
haploinsufficient utrophin mdx mice allow for longer term studies and have a larger window 
of correction when compared to mdx mice, due to the more severe phenotype. 
Another potential reason for the milder phenotype in mdx mice is the longer 
telomeres found in mice compared to humans, which could confer regenerative benefits.  
Telomeres shorten during replication, which limits the number of cell divisions and leads to 
senescence.  Even though muscle fibers are a post mitotic cell type, telomere length is 
important because the satellite cell population rapidly divides and expands in response to 
muscle damage.  In patients with DMD, telomere length is reduced, leading to a depletion of 
their satellite cell pool and contributing to disease progression (Decary et al., 2000).  In order 
to mimic human DMD progression mdx/mTR mice, which lack telomerase activity, have 
been made (Sacco et al., 2010).  Without telomerase, an enzyme that maintains telomere 
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length, the telomeres are markedly shorter and regenerative capacity is impaired.  The 
mdx/mTR mice have a more severe phenotype compared to the mdx mice since their 
capacity to repair disease related muscle damage is reduced.  
Besides the mdx utrophin and mdx telomerase knockout multiple other double-
knockout mice have been created.  Even though disease in double-knockout mice is more 
severe and better recapitulates the phenotype of DMD patients the genotypes of double-
knockouts and patients are more divergent.  Knockout of genes in the mdx mouse may make 
interpretation of experimental results more difficult because the new deletion could lead to 
confounding effects and make it more difficult to delineate the effect of dystrophin 
deficiency from that of the deficiency caused by the second mutation.  While mouse models 
are a good tool for proof of concept studies or to screen therapeutic strategies, it is difficult to 
move a treatment from mice directly into humans.  One of the difficulties arises from the 
much smaller size.  In the small mouse drugs may quickly defuse to the target tissue, but also 
drugs may be cleared faster due to the much higher metabolic rate compared to humans.  
Both of these facts make it difficult to convert the effective dose in mice to a dose for 
humans (Partridge, 2013).  Further, mice have a much milder immune response compared to 
humans.  Therefore strategies that are known to elicit an immune response in humans also 
need to be tested in a different animal model to ensure safety.  
The golden retriever muscular dystrophy (GRMD) model is closer in size to humans 
than the mouse, serving to facilitate the scaling up of drug doses.  The dystrophin gene in the 
GRMD model has a mutation in the 3′ end of intron six resulting in a splicing error in exon 
seven and a nonsense mutation in exon eight (Sharp et al., 1992).  As in DMD patients the 
GRMD has a progressive fatal phenotype (Kornegay et al., 2003).  Interestingly, GRMD 
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dogs have a high degree of phenotypic variability despite an identical causative mutation 
(Cooper et al., 1988, Shimatsu et al., 2003, Ambrosio et al., 2008, Zucconi et al., 2010), 
which may make difficult to find treatment effects or will require studies with very large 
numbers of dogs.  Since corticosteroids are the standard of care it may be beneficial to treat 
with steroids and an experimental treatment in a preclinical model to understand their 
possible interaction.  However, the GRMD dogs do not respond well to steroid therapy.  
Unlike in humans, steroids lead to calcified necrotic fibers and impairment of some measures 
of muscle function in the dog model (Liu et al., 2004, Drachman et al., 1974).  The different 
outcome of steroid treatment demonstrates that canine and human physiology is different.  
 The hypertrophic feline muscular dystrophy (HFMD) cat model for DMD is rarely 
used because animals die quickly due to the hypertrophy of the diaphragm or tongue.  There 
are different mutations resulting in HFMD but all are located at the muscle and purkinje 
promoter (Gambino et al., 2014, Winand et al., 1994).  
 The currently available animal models have contributed to our understanding of 
DMD and in the development of new therapeutic approaches.  But the large phenotypic 
variation or limited phenotypic similarity to patients as well as differences in size and drug 
response limits their usefulness in translational studies.  In order to move treatments from 
mice to humans a new animal model is needed.  A pig model seems to be a good 
consideration as pigs are closer in anatomy, physiology and genetics to humans than are mice 
or dogs.  The pig model could help eliminate unexpected challenges in clinical trials and 
assist in the scale up of treatments for clinical trials. 
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Current treatment for DMD 
The current standard of treatment for Duchenne muscular dystrophy is corticosteroid 
therapy with predisone or deflazacort (Moxley et al., 2005).  Corticosteroids were first tested 
in clinical studies 40 years ago (Drachman et al., 1974) but even with decades of study it is 
unclear from which molecular mechanisms the benefits of corticosteroids stem (Moxley et 
al., 2005).  Further, corticosteroids have severe side effects including weight gain, loss of 
bone density and mood swings.  Because of those side effects corticosteroids were not 
recommended for treatment of DMD at first (Dubowitz, 2013), however the benefits of 
prolonged mobility and increased pulmonary functions would seem to outweigh the side 
effects.  There are multiple steroid regimes prescribed with little consistency from clinic to 
clinic.  For example, steroids may be either administered in continuous daily treatments or 
with intermittent treatment and may involve periods of multiple days taking steroids followed 
by days without steroids.  These strategies have benefits and pitfalls; therefore it is important 
that the patient and his family become well informed to make the best decision.  
Nevertheless, corticosteroids do not fix the underlying genetic defect; therefore multiple 
therapeutic approaches are under investigation that aim to fixing the underlying cause of 
DMD by restoring dystrophin expression.  These approaches include nonsense mutation 
suppression, exon skipping, and gene therapy.  
 
Experimental treatment options 
 Mutations that cause premature stop codons are present in 15% of the DMD patients.  
Read-through of the premature stop codon could alleviate DMD in a subset of the total DMD 
population by allowing full length dystrophin to be made.  Gentamicin, an aminoglycoside 
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antibiotic, can interact with the ribosome facilitating the read-through of premature stop 
codons (Yoshizawa et al., 1998).  Indeed, gentamicin led to increased dystrophin protein 
abundance and improved muscle function in mdx mice (Barton-Davis et al., 1999).  
However, further studies and clinical trials with gentamicin were not as promising (Dunant et 
al., 2003, Politano et al., 2003, Wagner et al., 2001) and had mixed results (Malik et al., 
2010).  Even with some promising results long term aminoglycoside treatment should be 
carefully evaluated for its potential toxic effects, in the past both ototoxicity and 
nephrotoxicity have been reported (Selimoglu, 2007, Mingeot-Leclercq and Tulkens, 1999).  
The potential success of the read-through strategy has led to an effort to identify small 
molecules that can also facilitate the premature stop codon to be suppressed (Welch et al., 
2007, Kayali et al., 2012, Du et al., 2013).  The results of the small compound Ataluren 
(PTC124) has been promising in animal models and clinical trials (Finkel et al., 2013, Welch 
et al., 2007) however functional improvement was not observed in the clinical trial.  Also 
RTC13 seems to be promising in a first animal experiment (Kayali et al., 2012).  Even 
though this strategy shows potential the variable of results warrant a better understanding of 
the mechanism and sequence specificity to get efficient and repeatable read-through.  
Restoration of the functional dystrophin gene can also be achieved by interfering with 
the splicing machinery and excising the mutation, a process known as exon skipping.  Using 
this strategy, an antisense oligonucleotide (AO) binds to a pre-mRNA splice site of the exon 
to be skipped, masking the splice-site from recognition by the spliceosome, and leading to 
the desired exon being spliced out with its surrounding introns.  The DMD gene has a hot-
spot for disease causing mutations with 70% of deletions clustering in exons 45-55.  
Specifically, skipping exon 51 would restore the reading frame in 13% of all DMD patients, 
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which is the highest percentage that can be achieved with single exon skipping (Aartsma-Rus 
et al., 2009).  Drisapersen and Eteplirsen, two different drugs, have been tested in clinical 
trials to accomplish this task (Flanigan et al., 2014, Mendell et al., 2013, Goemans et al., 
2011).  The drugs were well tolerated and led to an increase in dystrophin and a modest 
improvement in the six minute walk test.  Both premature stop codon read-through and exon 
skipping are only applicable to a very small subset of DMD patients which is a limitation. 
 Gene therapy is applicable to all DMD patients independent of the causative 
mutation.  In this approach patient cells get supplemented with a functional copy of the 
dystrophin gene.  Gene transfer usually is accomplished by viral vectors that transfect the 
cells with the gene of interest.  Viral vectors include adenoviral, adeno-associated viral, and 
lentiviral vectors.  Adenoviral vectors are of limited usefulness for this purpose as they are 
not very effective in transfecting adult skeletal muscle and elicit a strong immune responds in 
humans (Raper et al., 2003), however they have a very large  carrying capacity (>30kb).  
Lentiviral vectors do not elicit an immune response, have an intermediate carrying capacity 
(9kb) but low transfection efficiency.  Further, random integration into the host genome 
could lead to tumor growth or damage to other genes.  Adeno-associated viral vectors have 
the smallest carrying capacity (>4.7kb) but are able  to transfect muscle and maintain 
transgene expression for at least one and at least up to seven years  (Rabinowitz and 
Samulski, 1998).  Other hurdles to overcome are the tissue specificity of different AAV 
serotypes, some are better at transfecting skeletal muscle where others are better at 
transfecting cardiac muscle, it is imperative that both skeletal as well as cardiac muscle get 
treated.  Also vector delivery to multiple muscles is challenging.  In some studies vector 
delivery was localized to an entire limb by excluding blood flow to the rest of the animal and 
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perfusing the vector in the limb resulting in localized muscle transfection (Greelish et al., 
1999, Ohshima et al., 2009).  To achieve systematic transfection of all skeletal muscle and 
the heart co-injection of AAV with VEGF, VEGF assists in vascular permeability has 
been effective in mice (Gregorevic et al., 2004) shows promise. 
The AAV and lentiviral vectors have a limited carrying capacity, ruling out the 
possibility to transfect the entire dystrophin coding region (11kb).  Interestingly, some BMD 
patients with a mild disease progression have substantial deletions of the dystrophin gene, 
resulting in a more than 50% reduction of the protein size (Matsumura et al., 1994, England 
et al., 1990).  Based on patients truncated dystrophin and the known function of the 
dystrophin domains, mini- and micro-dystrophins were developed.  Truncated dystrophins 
that fit in an AAV viral vector have been studied in several labs, demonstrating feasibility by 
improved pathology and force transduction in mdx or mdx/utr-/- mice (Sakamoto et al., 2002, 
Wang et al., 2000, Gregorevic et al., 2008, Gregorevic et al., 2006, Odom et al., 2011).   
Unlike in the mouse, in a clinical trial using AAV to deliver a microdystrophin to 
DMD patients no transgene was detected (Mendell et al., 2010a).  An immune response to 
dystrophin epitopes eliminated transgene expression.  Not only the transgene but also the 
viral vector can provoke an immune response to AAV in patients (Mendell et al., 2010b, 
Mingozzi et al., 2007), which interferes with transgene expression.  As transient immune 
suppression was able to allow the vector to transfect the muscle in dogs (Wang et al., 2007), 
a similar strategy may increase gene expression in humans as well.   
Recently multiple AAV have been administered simultaneously to create a larger 
dystrophin gene via recombination (Odom et al., 2011, Lostal et al., 2014).  In both studies 
the longer transcript, even full length dystrophin (Lostal et al., 2014), was observed.  
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However, due to the need of two or three vectors needing to transfect a single cell and the 
recombination having to take place the efficiency is rather low.   
Many studies have shown that it is beneficial to dystrophic muscle to intervene not 
only at the primary cause of the disease, missing dystrophin, but also with the secondary 
pathologies.  Due to the leaky sarcolemma of dystrophic muscle there is consequential 
increase in intracellular Ca
2+
.  A loss of Ca
2+
 homeostasis can lead to activation of proteases, 
mitochondria dysfunction, increased ROS production as well as increased inflammatory 
response.  
 Inhibition of calpain proteases by either small molecules or calpastatin over-
expression decreases dystrophic pathology (Lescop et al., 2005, Spencer and Mellgren, 
2002).  However, other studies have not shown similar benefits (Childers et al., 2011, Selsby 
et al., 2010).  Therefore, it has been postulated that calpains have a highly regulated set point, 
up regulating themselves to reach that point if inhibition is incomplete (Hollinger and Selsby, 
2013).  The proteasome, which normally digests the calpain cleavage products, has also been 
inhibited with mixed results (Selsby et al., 2012b, Gazzerro et al., 2010, Briguet et al., 2008, 
Bonuccelli et al., 2003).  Some studies have reported the accumulation of DGC components 
at the sarcolemma, which may explain some of the observed benefits.  Nevertheless, 
dystrophic muscle is under acute stress and inhibition of proteases may exacerbate the 
dysfunction by accumulating large amounts of non- or poorly functional proteins.  Support 
for this argument can be seen by the fact that increased autophagy, not reduced autophagy, is 
beneficial to dystrophic muscle (De Palma et al., 2012, Pauly et al., 2012).   
 Mitochondrial Ca
2+
 overload can lead to necrosis and metabolic dysfunction in 
dystrophic muscle (Wrogemann and Pena, 1976).  Stabilizing the mitochondria and 
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preventing the mitochondrial dysfunction due to Ca
2+
 overload can improve the pathology in 
mdx mice (Wissing et al., 2010, Millay et al., 2008).  Idebenone, an antioxidant that also has 
mitochondrial function had positive outcomes in a clinical trial, including increased 
respiratory and cardiac function (Buyse et al., 2011).  These studies demonstrate the potential 
of improved energy metabolism and mitochondrial function for treatment of dystrophic 
muscle.  Further it shows on the example of Idebenone that a treatment can have a 
combination of benefits, inhibiting ROS and improving mitochondrial function since one 
could be causative of the other.   
 Further evidence for the interplay of different pathways was shown by treatment of 
mdx mice with the antioxidant n-acetylcysteine.  Treatment led to a reduction in ROS and in 
inflammatory NF-ƙB both contributing to improved muscle function (Whitehead et al., 
2008). Also the reduction in ROS was able to prevent exercise induced injury in dystrophic 
mouse muscle (Terrill et al., 2012). 
Another treatment strategy is to up regulate proteins with functional redundancy to 
dystrophin.  Integrins form a complex similar to the DGC, also aiding in force transduction 
during contraction, by connecting the cytoskeleton to the extracellular matrix.  Hakim at al. 
(Hakim et al., 2013) reasoned that if the integrins have a redundant function to the DGC 
knocking them out would exacerbate the dystrophic phenotype.  Therefore, they evaluated 
mdx, α7-integrin knockout, and the mdx/α7-integrin double knockout.  Consistent with their 
hypothesis the double knock out had  more pronounced histopathology and muscular 
dysfunction compared to both single knockouts (mdx or α7-integrin knockout) (Hakim et al., 
2013).  Conversely, increased expression of α7-integrin reduced dystrophic pathology and 
improved muscle function (Burkin et al., 2005, Heller et al., 2013, Burkin et al., 2001).  
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Burkin et al. used transgenic over expression of α7-integrin in the mdx/ utr-/- and 
demonstrated an increased life span and prolonged mobility (Burkin et al., 2001).  The 
beneficial effects of α7-integrin over-expression were independent of DGC restoration to the 
sarcolemma, supporting the notion of some functional redundancy of the integrin complex 
and DGC (Burkin et al., 2005).  Viral over-expression of α7-integrin in mdx mice was able to 
prevent contraction induced injury, which supports that the integrin complex can lead to 
stabilization of the sarcolemma (Heller et al., 2013). 
 
Utrophin 
 Dystrophin has an autosomal paralogue, utrophin (Love et al., 1989), which share an 
80% sequence homology though at only 395 kDa, utrophin is smaller compared to dystrophin 
(427 kDa) (Tinsley et al., 1992).  Similar to dystrophin, utrophin has an N-terminal actin 
binding domain, a rod domain with spectrin like repeats and a cysteine rich domain as well as 
C-terminal domain that can interact with the DGC.  Some of the differences are found in the 
rod domain.  Utrophin has only two hinge regions were dystrophin has four.  Also, due to 
differences in the spectrin like repeats utrophin cannot localize nNOS to the sarcolemma (Li 
et al., 2010).  Utrophin interacts with actin differently (Rybakova et al., 2002) as it only has 
one actin binding domain compared to two in dystrophin, however that does not seem to 
influence the strength of the interaction.   
Like dystrophin, utrophin has differing promoters that slightly alter the gene product.  
Utrophin A regulates gene expression at the synapse where promoter B seems to lead to 
utrophin expression in vascular epithelia cells (Weir et al., 2002).  The activation of utrophin 
promoter B is not as well understood.  The utrophin A promoter consists of a N-box which 
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can interact with GA-binding protein found at the NMJ (Gramolini et al., 1999) and an E-box 
which can interact with myogenic transcription factors initiating expression during muscle 
development or regeneration (Perkins et al., 2001).  The promoter can explain the different 
localization of utrophin and dystrophin within healthy skeletal muscle.  Utrophin is localized 
to the neuromuscular junction in adult muscle and is only found throughout the sarcolemma 
in regenerating muscle whereas dystrophin is generally found along the sarcolemma in 
healthy adult muscle (Nguyen et al., 1991).  Further, utrophin expression is increased in slow 
compared to fast skeletal muscle (Gramolini et al., 2001).  This difference stems from 
different post-transcriptional regulation since transcription rates are similar in slow and fast 
muscle.  Interestingly, slow muscle fibers are less affected by DMD (Webster et al., 1988).  
Not only do slow fibers have increased utrophin abundance compared to fast but also other 
structural proteins. 
To test if utrophin could substitute for the missing dystrophin protein, mdx mice with 
transgenic over-expression of truncated utrophin or full length utrophin were generated 
(Tinsley et al., 1998, Tinsley et al., 1996).  Both restored the DGC and improved 
histopathology and increased expression of the full length utrophin transgene increased 
muscle function.  The same group found complete functional recovery with a muscle specific 
transgene (Rafael et al., 1998).  However, studies with inducible muscle specific transgenes 
did not completely inhibit dystrophic injury.  When the transgene was induced 10 days or 30 
days after birth and muscles evaluated at three month of age even though the DGC was 
localized to the sarcolemma some muscle dysfunction persisted (Squire et al., 2002).  In the 
non-inducible muscle specific transgenic animals levels of utrophin expressed were much 
higher and also the expression started in utero which could account for the difference 
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observed between the two studies.  Postnatal somatic viral gene transfer of microurophin into 
four week old mdx/utr-/- has shown that utrophin can ameliorate dystrophy and improve 
muscle function when administered after birth (Odom et al., 2008).    
By fusing a microutrophin protein to a TAT domain, the protein transduction 
domain of the HIV-1 TAT protein, the microutrophin can cross the cell membrane.  
Sonnemann et al. demonstrated that injection of the microurtopin- TAT construct allowed for 
DGC assembly at the sarcolemma (Sonnemann et al., 2009).  In a follow up study the same 
group showed that the microurtopin- TAT protein could also modulate life span and muscle 
function of the mdx/ utr-/- (Call et al., 2011).  Based on the benefits of increased utrophin 
expression, but the limitations of the previously described studies for human treatment, 
Chancellor et al. used cell based drug screening to develop a small orally bioavailable 
substance that can increase utrophin expression (Chancellor et al., 2011).  That substance, 
SMT C1100, was subsequently tested in mdx mice and demonstrated its ability to increase 
utrophin protein abundance, improve histopathology and muscle function (Tinsley et al., 
2011). A SMT C110 clinical trial is currently is ongoing.   
 
Peroxisome proliferator-activated receptor γ coactivator 1α 
 As discussed, increased utrophin expression can correct the disease phenotype.  The 
validity of this approach has been demonstrated in multiple studies in DMD animals, 
however currently there is no approved way to achieve increased utrophin expression in the 
DMD patient population.  Since slow muscles have increased utrophin expression driving the 
slow myogenic program may be a good way to increased utrophin protein abundance.  
Peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) has been implicated in 
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exercise related muscle–type switching, which was verified by transgenic PGC-1α over 
expression in healthy mice (Lin et al., 2002).  Therefore PGC-1α seems to be a great 
candidate to drive the slow muscle program in dystrophic muscle and induce utrophin 
expression as part of that slow muscle program.  Handschin et al. demonstrated in cell culture 
that PGC-1α facilitates assembly of the GA-binding protein which can drive utrophin gene 
expression by interacting with the N-box domain in the promoter region (Handschin et al., 
2007).  In the same study Handschin et al. created mdx mice with transgenic PGC-1α over-
expression.  These mice had decreased muscle injury and lower CK after a bout of in vivo 
induced eccentric contraction injury.  Taken the injury prevention together with cell culture 
work from Handschin et al. increased utrophin expression is the likely reason mdx mice with 
transgenic PGC-1α over-expression had less muscle damage.  Since there was a benefit of 
PGC-1α an AAV vector was used in mdx mice, to better understand PGC-1α-mediated 
benefits. Neonatal mdx mice were transfected with an AAV6 driving expression of PGC-1α 
(Selsby et al., 2012a).  Selsby et al. found that PGC-1α drove a slow oxidative muscle 
program including increased utrophin protein abundance.  Histopathology and resistance to 
injury caused by eccentric contraction were improved.  While both studies increased 
successfully used increased PGC-1α expression, this was done either in utero or early in an 
animal’s life.  When patients are diagnosed they already have muscle dysfunction.  Indeed, 
they are diagnosed precisely because of that dysfunction.  Hence, it is necessary to consider 
the capacity of an intervention to rescue already declining muscle from further disease-
related injury.  Toward that end, six week old mdx mice were subjected to PGC-1α gene 
transfer via electroporation of a plasmid.  Similar to above, this group found improved 
mitochondrial function (Godin et al., 2012).  This study was limited however, as at the six 
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week time point hind limb muscle is no longer experiencing disease related decline but is 
well into the regenerative period.  Further, no additional measures to assess disease 
progression were included.  Hence, there remains a critical need to determine the extent to 
which PGC-1α gene transfer rescues muscle from disease-related injury.   
 While gene transfer approaches, for this gene as well as others, including dystrophin, 
hold tremendous promise in the future the DMD population urgently needs drugs that will 
allow them to arrive at that future date when gene transfer can occur.  Hence, there is interest 
in identifying drugs that can also drive the PGC-1α pathway.  One of those drugs is 
GW501516, a peroxisome proliferator-activated receptor (PPAR) beta/delta agonist.  
Treatment of mdx mice with GW501516 showed the expected fiber-type shift, probably via 
increased PGC-1α (Miura et al., 2009, Jahnke et al., 2012).  Further, utrophin was increased 
and the DGC assembled at the sarcolemma, which led to decreased susceptibility to eccentric 
contraction injury (Miura et al., 2009).  Miura et al. demonstrated that the PPAR response 
element, part of the utrophin promoter, is needed to drive utrophin expression by GW501516.  
The slow oxidative switch after GW501516 treatment was validated by Jahnke et al. as they 
further found decreased inflammation and increase mitochondrial function with GW501516 
treatment of mdx mice (Jahnke et al., 2012).  Despite that the fact the PPAR agonists are 
currently used in treatment of type 2 diabetes, they have numerous side effects including 
weight gain, bone loss and heat failure (Ahmadian et al., 2013).  These side effects need to be 
considered especially since DMD patients are predisposed to heart problems.  An AMP-
activated protein kinase (AMPK) activator, activator 5-aminoimidazole-4-carboxamide-1-β-
D-ribofuranoside (AICAR), has also been shown to drive the slow muscle program in healthy 
muscle.  AICAR administration to mdx mice led to a slow muscle type shift as well as 
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increased utrophin and PGC-1α expression (Pauly et al., 2012, Ljubicic et al., 2011).  While 
these drugs are promising none of them are approved for clinical use, which will delay 
implementation to this population.  Hence, nutraceuticals may provide an immediate route to 
therapy.  Resveratrol is an orally available naturally occurring phenolic Sirt-1 activator, Sirt-
1 which in turn can activate PGC-1α (Milne et al., 2007).  Indeed, Hori et al. found 
resveratrol to beneficial in dystrophic muscle by decreasing ROS (Hori et al., 2011).  Gordon 
et al. demonstrated that resveratrol can increase utrophin and PGC-1α mRNA (Gordon et al., 
2013).  In a second, longer term study the same group found functional improvements but did 
not observe changes in oxidative capacity (Gordon et al., 2014).  Selsby et al. reported only 
minimal improvements of muscle function after resveratrol treatment (Selsby et al., 2012a), 
further at a dose of 400 mg/kg mice died.  Interestingly Gordon et al. did not report any 
toxicity of resveratrol at a 500 mg/kg.  However, the potential toxicity may limit the 
usefulness of resveratrol in treating DMD.  Quercetin is also an orally available naturally 
occurring Sirt-1 activator.  In healthy muscle quercetin can up regulate PGC-1α mRNA 
(Davis et al., 2009) and improved mitochondrial function is also observed in muscle of obese 
mice (Henagan et al., 2014).  Therefore quercetin could have great potential for dystrophic 
muscle by leading to a muscle type shift via PGC-1α. 
 
Conclusion 
Current treatment options for DMD are inadequate and only corticosteroids have 
FDA approval.  Even though multiple treatments have been successful in treating animal 
models of DMD few have been tested in clinical trials and none have been approved for 
human use.  Therefore, there is a need for treatments that can be readily applied to the patient 
21 
 
population.  To this end the PGC-1α pathway is a promising avenue for treatment as it can 
prevent both primary and secondary pathologies of DMD.  However, it is unknown if PGC-
1α can rescue dystrophic muscle with ongoing necrosis.  This is of particular importance 
since most patients are diagnosed precisely because of muscle dysfunctions.  Quercetin is an 
orally available, safe nutraceutical that activates the PGC-1α pathway in healthy mice and 
could be a way to translate PGC-1α-based treatments quickly to the patient population.  
Contributing to the failure to generate new drugs for clinical application are the 
limitations of current animal models for DMD.  Of note, no animal models for BMD are 
available.  This need is becoming more urgent as many of the experimental treatments for 
DMD will convert DMD patients to the milder BMD phenotype.  Therefore, there is a critical 
need for a novel large animal model of dystrophinopathies in order to aid in drug 
development for dystrophinopathy patients and better understand disease progression in 
BMD. 
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CHAPTER 2.  RESCUE OF DYSTROPHIC SKELETAL MUSCLE BY PGC-1α 
INVOLVES RESTORED EXPRESSION OF DYSTROPHIN ASSOCIATED 
PROTEIN COMPLEX COMPONENTS AND SATELLITE CELL 
SIGNALING 
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Abstract 
Duchenne muscular dystrophy is typically diagnosed in the preschool years because 
of locomotor defects, indicative of muscle damage.  Thus, effective therapies must be able to 
rescue muscle from further decline.  We have previously established that Peroxisome 
proliferator-activated receptor gamma co-activator 1-alpha (PGC-1α) gene transfer will 
prevent many aspects of dystrophic pathology, likely through up-regulation of utrophin and 
increased oxidative capacity, however, the extent to which it will rescue muscle with disease 
manifestations has not been determined.  Our hypothesis is that gene transfer of PGC-1α into 
declining muscle will reduce muscle injury compared to control muscle.  To test our 
hypothesis AAV6 driving expression of PGC-1α was injected into single hind limbs of three 
week old mdx mice while the contralateral limb was given a sham injection.  At six weeks of 
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age, treated soleus muscle had 37% less muscle injury compared to sham-treated muscles 
(p<0.05).  Resistance to contraction induced injury was improved 10% (p<0.05) and was 
likely driven by the 5-fold (p<0.05) increase in utrophin protein expression and related 
increase in dystrophin associated complex members.  Treated muscles were more resistant to 
fatigue, which was likely caused by the corresponding increase in oxidative markers.  PGC-
1α over-expressing limbs also exhibited increased expression of genes related to muscle 
repair and autophagy.  These data indicate that the PGC-1α pathway remains a good 
therapeutic target as it reduced muscle injury and improved function using a rescue 
paradigm.  Further, these data also indicate that the beneficial effects of PGC-1α gene 
transfer may be far more complex than increased utrophin expression and oxidative gene 
expression. 
 
Key Words:  Duchenne muscular dystrophy, utrophin, gene expression, oxidative, mdx 
 
Introduction 
Caused by a mutation in the dystrophin gene, Duchenne muscular dystrophy (DMD) 
is the most common fatal X-linked disease.  In healthy muscle the dystrophin protein serves 
as a functional link between the actin cytoskeleton and the extracellular matrix (ECM) 
through the dystrophin-associated protein complex (DAPC) (8, 11, 49).  Production of an 
aberrant protein product results in a failure to adequately transmit forces to the ECM and 
results in damage to the sarcolemma, particularly during lengthening contractions, as well as 
a number of secondary effects.  In addition to a failure to maintain calcium homeostasis, 
metabolic dysregulation is also associated with the disease (17, 32).  The culmination of 
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these cellular events is impaired muscle function (39, 54, 55) as contractile tissue is 
progressively replaced by adipose and fibrotic tissue (14).  DMD is typically diagnosed in 
preschool-aged boys, after the child shows impaired motor function. Patients are often 
wheelchair bound by age twelve and succumb to the disease due to respiratory complications 
or cardiomyopathy in the early twenties (15).  
DMD is modeled by the mdx mouse, which has a nonsense mutation in exon 23 (7, 
56).  While the mdx mouse is dystrophin deficient it generally suffers a far milder phenotype 
than typical DMD patients.  For example, there is generally no fatty infiltration into muscle, 
the lifespan is only moderately reduced (~20%), and mobility is generally not affected (9).  
The mdx mouse, however, does accurately recapitulate many aspects of the disease for a 
brief time in the hind limb muscles while the diaphragm suffers a steady disease progression 
like is observed in human patients (13, 57).  Among the proposed explanations for the mild 
phenotype of mdx mice compared to DMD patients is that mdx mice have higher utrophin 
expression (26).  Utrophin is an autosomal dystrophin-related protein that is expressed at the 
neuromuscular junction (NMJ) in healthy muscle cells (20, 25).  Since utrophin has a similar 
structure to dystrophin (N and C termini, spectrin-like repeats, and hinge regions) it has been 
suggested that utrophin can serve as a functional substitute for dystrophin in dystrophic 
skeletal muscle (44, 61).  Indeed, dystrophin deficient mice transgenically overexpressing 
utrophin and utrophin gene transfer in animal models have shown convincingly that 
increased utrophin expression will prevent/delay disease onset and rescue already declining 
muscle (23, 46, 60, 63) from some, but not all dystrophic pathologies (29).  Currently, 
however, a practical means of increasing utrophin expression is lacking for human patients.     
38 
 
Activation of the transcriptional co-regulator, Peroxisome proliferator-activated 
receptor gamma co-activator 1-alpha (PGC-1α), promotes the expression of utrophin at the 
NMJ as well as more widely throughout the sarcolemma (2, 19).  Importantly, PGC-1α also 
regulates mitochondria biogenesis and promotes the expression of oxidative genes, which 
may help to offset metabolic dysregulation observed in dystrophic skeletal muscle (17, 27, 
32, 65).  Moreover, PGC-1α has also been shown to lead to expression of antioxidants, which 
may help to reduce free radical injury and maintain muscle function (21, 55, 64).  Indeed, 
dystrophin-deficient mice transgenic for increased PGC-1α and gene delivery of PGC-1α into 
neonatal mdx skeletal muscle have reduced muscle injury and improved muscle function 
compared to untreated muscle (22, 52).   
These early successes are promising and indicate that PGC-1α over-expression will 
prevent disease onset.  However, as most patients are diagnosed precisely because they have 
functional impairments, it indicates that they already have advanced disease-related injury 
sufficient to impact locomotion.  Hence, it is important that interventions not only prevent the 
disease from developing but also prevent continued decline and potentially even restore 
muscle function if initiated following the onset of muscle injury.  In a recent investigation 
PGC-1α gene transfer was performed in 6 wk old muscle in mdx mice (18).  While ultimately 
effective in improving a number of pathological outcomes, 6 wk old muscle is well into the 
regenerative phase of the early necrotic bout, hence the extent to which PGC-1α alters typical 
pathology in actively declining muscle remains unknown.  The aim of this study is to 
determine the extent to which PGC-1α gene transfer rescues dystrophic muscle from typical 
disease related decline during the initial necrotic bout.  This purpose represents an important 
next step in a line of inquiry advancing PGC-1α pathway activation toward therapeutic 
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application for DMD patients.  Our hypothesis is that dystrophic skeletal muscles over-
expressing PGC-1α will have less muscle injury and improved function compared to 
untreated muscles indicating successful rescue of disease progression.   
 
Methods 
Animal Treatments.  All animal procedures were approved by the IACUC at Iowa 
State University and were done in accordance with the guiding principles established by the 
American Physiological Society.  To determine the extent to which PGC-1α gene transfer 
can rescue dystrophic muscle from disease related decline three week old dystrophin-
deficient (mdx) mice were obtained from our colony.  We have found that mdx mice from 
our colony begin to exhibit early signs of muscle injury at approximately this time.  Mice 
were given a 50 µl injection in a single triceps surae containing 1x10
11
 genome copies of 
adeno-associated virus (AAV) serotype six driving expression of PGC-1α under the control 
of a modified chicken beta actin promoter (52).  We have previously used a similar technique 
to achieve infection of the muscles of a single limb while the contralateral limb remained 
uninfected (52, 55).  The contralateral limb was injected with empty vector.  At six weeks of 
age animals were brought to a surgical level of anesthesia with tribromoethanol, the soleus 
muscles removed, and the mouse sacrificed by cervical dislocation.  Soleus muscle pairs 
were randomly assigned to either biochemistry, and snap frozen in liquid nitrogen, or 
histology, and coated in freezing media and frozen in melting isopentane.  In addition, a 
subset of animals were treated and designated for muscle function measures.   
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Histology.  Ten-micron frozen sections were cut from soleus muscles and placed on 
slides.  Hematoxylin and Eosin staining was performed according to standard techniques.  
Each soleus muscle was visualized using a Leica microscope at 100x and multiple pictures 
taken such that the entire soleus was captured, generally using 3-5 images.  Complete soleus 
muscles were digitally reconstructed using Photoshop so that the entire muscle cross section 
was in a single picture file and could be readily analyzed.  The reconstructed image was 
imported into OpenLab so that areas of immune cell infiltration, hypercontracted cells, and 
H&E negative cells could be quantified.  These areas are expressed as a percentage of the 
total muscle cross sectional area. H&E sections were further used to determine central 
nucleation.  Briefly, the total number of muscle fibers and the total number of muscle fibers 
with centralized nuclei were counted in the reconstructed image using Image J.  The total 
number of fibers with a centralized nucleus was made relative to the total number of fibers in 
the cross section and the resulting percentage reported.  Counts were made by a blinded 
technician.   
 To identify utrophin protein localization and measure expression, slides were probed 
with antibody for utrophin (Vector VP-U579) directly labeled with Zeon Alexa 568 
(Invitrogen Z25006).  Slides were washed in PBS for 10 min and blocked for 15 min with 
5% BSA.  They were then exposed to labeled primary antibody (1:10) in 1% BSA and 
incubated for 60 min at room temperature in the dark.  Slides were washed three times for 10 
min in PBS.  Coverslips were mounted using Vectarshield with DAPI.   
Utrophin expression and localization was visualized in 2-3 random sections/muscle at 
400x.  Importantly, all slides were prepared at the same time and all images were taken using 
identical exposure conditions on the same microscope in random order.  To quantify utrophin 
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expression images were imported into OpenLab and the density slice function used to 
transform the image into a binary image.  In this fashion, pixels are identified as either above 
or below threshold intensity.  Threshold was determined by measuring pixel intensity of 
intracellular and extracellular areas where there should be no utrophin expression as well as 
utrophin expression at several locations on the sarcolemma in several random sections.  
Importantly, all images were processed under identical conditions.  For sections from control 
soleus muscles the replicate with the greatest utrophin expression was used for analysis.  
Conversely, for the PGC-1α treated limbs the corresponding replicate with the lowest 
utrophin expression was used for analysis.  The total area of utrophin expression that 
exceeded threshold was quantified and is expressed relative to control.  As we compared the 
greatest utrophin expression from control soleus muscles to the lowest utrophin expression 
from corresponding treated muscles our measurement of relative utrophin expression is likely 
conservative. 
To determine fiber area distribution slides were washed and blocked as described 
above. Overnight, sections were exposed to a primary antibody for laminin (NeoMarkers, 
RB-082-A) at a dilution of 1:100.  Slides were then washed and secondary antibody applied 
for 1 hour at room temperature.  Secondary antibody, (goat anti-rabbit-rhodamine 
conjugated; Millipore, 12-10) was used at a dilution of 1:100.  Two random and non-
overlapping images were taken of each section at 200x.  Using Image Pro, minimum Feret 
diameter was measured in each complete cell in these images and resultant data pooled for 
each muscle resulting in the inclusion of 100-180 fibers/muscle.  Average fiber diameter was 
calculated as was the coefficient of variance (6).  
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Muscle Function.  Muscle function (tetanic force, a series of eccentric contractions, 
and fatigue) was measured in the soleus at the Physiological Assessment Core of the 
Wellstone Muscular Dystrophy Cooperative Center at the University of Pennsylvania 
according to standard techniques (3, 4, 36, 39, 52-55).  Solei from different animals were 
used to measure eccentric injury and fatigue resistance so that one measure would not 
interfere with the other.  Force produced during these measures is normalized to the force 
produced during the initial contraction.  Importantly, technicians performing these measures 
were blinded to the treatments. 
Biochemistry.  RNA was isolated from soleus muscles using Trizol following 
manufacturer recommended instructions.  Purified RNA was further processed using Qiagen 
RNesay spin columns.  Using the RT
2
 First Strand Kit (SABiosciences) c-DNA was 
synthesized from 1µg of purified RNA, following manufacturer’s instructions.  
Subsequently, we performed quantitative PCR (qPCR) to determine PGC-1α expression in 
treated and control limbs using the 18S ribosomal subunit as a loading control.  We also 
measured expression of the autophagy markers Lc3 (Map1lc3a), Atg 12, Bnip 3 and Gabarap 
1 in a similar manner.  Additionally, cDNA was loaded into SABioscience Mouse Skeletal 
Muscle: Myogenesis and Myopathy array (PAMM-099A) and qPCR reactions run according 
to manufacturer recommendations.  The array is a 96 well PCR plate seeded with mouse 
specific primer pairs for 84 genes with known function in skeletal muscle myogensis and 
myopathy.  These primer pairs have been extensively tested for target specificity, according 
to the manufacturer.  Expression of all significantly different genes was increased, however 
genes on the array were chosen because of their known involvement in pathological 
processes.  In addition, the array includes controls for genomic contamination, successful 
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reverse transcription, and a control to verify successful qPCR, as well as suggested loading 
controls.  Importantly, expression (CT value) of these loading controls, Gapdh and β-actin, 
was altered by our intervention.  To determine an appropriate loading control we compared 
CT values of all of the genes on the plates and chose titin and Slc2a4 because they had a 
combination of the highest p-value and smallest fold change.  In order to provide the most 
robust loading control we normalized to the mean expression of these genes.  Normalization 
to the 18S subunit was not possible because primers to the 18S subunit were not part of the 
array.  Delta (∆) CT values were calculated by subtracting the CT value from the 
experimental gene from the CT value of the control.  These values were used for statistical 
comparisons.  ∆∆CT was calculated by subtraction of the ∆CT of a treated soleus muscle 
from the ∆CT of the corresponding control soleus muscle.  Data are presented as fold change 
as calculated by ∆∆CT.  Data points more than two standard deviations from the mean were 
excluded regardless of direction (above or below mean) or group resulting in the exclusion of 
17/534 data points.  
Statistics.  Differences in muscle fatigue were evaluated with PROC MIXED in SAS.  
Remaining data were compared using paired t-tests.  Significance was set at p<0.05.  All data 
are expressed as means ± SEM unless otherwise noted.   
 
Results 
In order to increase expression of PGC-1α a virus driving PGC-1α expression was 
injected into a single hind limb of three week old mdx mice while the contralateral limb was 
injected with a null virus containing empty capsid.  The three week old time point was 
chosen because soleus muscles from mdx mice in our colony show early signs of disease-
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related muscle injury, including immune cell infiltration and degeneration (Figure 1).  
Similar findings of early necrotic changes in limb muscles at this time point have been 
reported by others (7, 33, 45, 47). Three weeks following viral injection our gene delivery 
technique successfully increased expression of PGC-1α in soleus muscles from treated limbs 
compared to soleus muscles from null limbs by approximately 11-fold (Figure 2; p<0.05).  
Soleus muscle mass was similar between groups (Null – 6.2 ± 0.2 mg; PGC-1α – 6.1 ± 0.2 
mg; n=29) however, PGC-1α gene transfer caused a reduction in gastrocnemius mass 
compared to null virus treated limbs (Null – 102.7 ± 3.6 mg; PGC-1α – 97.0 ± 3.4 mg; 
p<0.05; n=29).  The large sample number reported for this measure is a combination of 
muscles used for histological, biochemical, and functional analyses.   
Visual inspection of H&E stained muscle cross sections revealed disease-related injury to 
both null treated and PGC-1α treated limbs including foci of necrosis with apparent immune 
cell infiltration, hypercontracted cells, and H&E negative staining fibers (Figure 3).  To 
determine the extent to which PGC-1α altered muscle condition these areas were quantified.  
We found that areas of immune cell infiltration were reduced by 31% (p<0.05), areas of 
hypercontracted cells by 65% (p<0.05), and areas of H&E negative cells by 43% (p<0.05) in 
PGC-1α over-expressing soleus muscles compared to null-virus treated soleus muscles.  In 
aggregate, this reduced the total area of damaged muscle by 37% (p<0.05). The percentage of 
cells with centralized nuclei was similar between groups.  Fiber area distribution was also 
similar between groups (Figure 4) as was mean minimum Feret diameter and coefficient of 
variation.   
As total damaged area was decreased in limbs over-expressing PGC-1α we 
determined the extent to which PGC-1α gene transfer would rescue muscle function in 
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already declining muscle.  Cross sectional area, tetanic force, and specific tension were 
similar between groups (Table 1).  As there is rationale to suspect that PGC-1α can lead to 
utrophin expression and resultant resistance to contraction induced injury we measured force 
production in five eccentric contractions.  Solei over-expressing PGC-1α were able to 
produce approximately 10% more (p<0.05) force than control solei during each contraction 
(Figure 5).  To determine the extent to which PGC-1α over-expression rescued mdx muscle 
from fatigue, muscles underwent an endurance challenge. PGC-1α over-expressing solei 
maintained significantly higher force throughout the protocol (p<0.05) (Figure 6).  
 To better understand the mechanism underlying histological and functional rescue of 
dystrophic soleus muscles we measured content and localization of utrophin protein using 
immunohistochemistry.  PGC-1α gene transfer resulted in a nearly 5-fold (p<0.05) increase 
in utrophin expression compared to null treated soleus muscles (Figure 7).  Importantly, this 
increase in utrophin was not localized to the neuromuscular junction as utrophin was found 
throughout the sarcolemma.   
Because PGC-1α is a transcriptional co-activator it has the potential to alter 
expression of numerous genes, hence we performed a PCR array.  A PCR array is a 96 well 
plate preloaded with primers, in this case, for 84 genes involved in myogenesis and 
myopathy.  This array (PAMM-099A, SABiosciences) was selected specifically because it 
contains primers for genes related to the dystrophin-glycoprotein complex, energy 
metabolism, and myogenesis, among other processes.  While many of these processes are 
grounded with sound hypotheses (i.e. increased expression of genes related to the DAPC and 
oxidative metabolism), this approach allowed us to better understand the widespread cellular 
effects underlying PGC-1α-mediated rescue.  Genes whose products are directly or indirectly 
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associated with dystrophin and the DAPC were increased approximately 50% (range 33% - 
85%) in soleus muscles over-expressing PGC-1α compared to control muscles (Figure 8).  
Expression of several sarcomeric genes was increased though expression varied widely from 
16% - 2-fold over control soleus muscles (Figure 8). Expression of metabolic genes was 
increased 18% - 85% in soleus muscles from treated limbs compared to soleus muscles from 
control limbs (Figure 9) though some metabolic genes failed to reach significance (Table 2).  
Genes related to satellite cell function were increased 31% - nearly 2-fold in soleus muscles 
over-expressing PGC-1α compared to control soleus muscle (Figure 10).  There was a 
modest increase in genes associated with calcium-mediated protein degradation as well as the 
atrogenes Fbxo 32 (Atrogin-1, MAFbx) and Trim 63 (MuRF 1) that was countered by an 
increase in genes associated with protein synthesis in treated limbs compared to control limbs 
(Figure 11). Surprisingly, inflammatory signaling was generally increased in treated limbs 
compared to control limbs.  Tnf expression was increased 34-fold in treated limbs compared 
to control limbs and Il6 and Il-1β were increased by 4- and 8-fold, respectively (Figure 12).  
Also pro-apoptotic caspase 3 was increased by an approximate 2.6-fold, however was well 
matched with a similar increase in the antiapoptotic Bcl2 and αB crystalin (Figure 12).   
Given recent findings using a similar, but distinct approach(43), we also measured 
expression of genes related to autophagy.  PGC-1α gene transfer caused a 50% and 86% 
increase in Lc3 (p<0.05) and Atg12 (p<0.05), respectively, however, the autophagy genes 
Bnip3 and Gabarap 1 were similar between treated and control soleus muscles (Figure 13).   
Expression of genes that were similar between groups can be found in table 2.   
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Discussion 
Duchenne muscular dystrophy is caused by a mutation in the dystrophin gene giving 
rise to a non-functional protein product.  Novel therapies approved for human use have been 
slow in coming, however, numerous experimental approaches are present in the literature (1, 
5, 38, 39, 53-55).  Among the most successful is replacing the missing dystrophin protein 
with utrophin, a dystrophin-related protein (23, 46, 60, 63).  While several strategies for 
potential use in humans are advancing (24, 35, 62), their approval is not imminent and drugs 
may prove ultimately unsuccessful.  It is, therefore, critical to continue searching for 
pathways that can be modulated for therapeutic benefit.  One possible solution is to increase 
expression of the co-activator, PGC-1α, as previous work indicates PGC-1α drives utrophin 
expression through an N-box domain in the utrophin promoter (2, 22, 37).  As well as 
increased utrophin expression, PGC-1α also drives expression of oxidative proteins and 
antioxidants (21, 28, 64), which may be therapeutic to dystrophic muscle as metabolic 
dysregulation has been repeatedly reported (17, 27, 32, 65).  Moreover, as PGC-1α is a 
transcriptional co-activator there is a likelihood that it will drive expression of additional 
genes that provide further means of disease mitigation.   
An important consideration during therapy development is that DMD patients are 
generally diagnosed during the preschool years when they display locomotor deficits 
indicating that their muscles have already been damaged by the disease.  Hence, 
interventions must have the potential to rescue declining muscle from continued disease-
related muscle injury.  We (52), and others (22), have previously established that increased 
PGC-1α expression prior to muscle injury reduced the severity of disease and preserved 
muscle function compared to control muscles.  Recently, it was shown that PGC-1α gene 
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transfer enhanced recovery from the initial necrotic bout experienced in the mdx model (18), 
however, as the intervention began when muscles would be predicted to be well into the 
recovery phase little is known about the capacity of PGC-1α to protect actively declining 
muscle.  In this investigation our purpose was to extend these observations and determine the 
extent to which increased PGC-1α expression rescued already declining muscle from 
continued disease related muscle injury.  
Our injection technique increased PGC-1α expression by approximately 11-fold 
compared to control limbs.  PGC-1α expression measured by PCR array was similar between 
groups.  Resolution to this discrepancy is that the array targets primers to the 3' UTR of the 
transcriptional product, which is lacking in the viral construct.  In contrast, our primers are 
targeted to the middle of the transcriptional product.  That endogenous gene expression is 
similar between limbs indicates that our intervention does not alter expression of endogenous 
PGC-1α.   
 We found that gene transfer of PGC-1α into already declining muscle rescued 
dystrophic muscle from typical disease progression and specifically reduced the areas of 
immune cell infiltration, hypercontracted cells, and H&E negative staining fibers.  
Additionally, PGC-1α over-expression led to resistance to fatigue and injury caused by 
eccentric contractions.  Previously, we found that PGC-1α gene transfer to neonates 
protected the EDL from eccentric injury, but not the soleus (52).  This subtle difference could 
stem from a more substantial increase of utrophin protein in the current study.  Further 
inconsistencies are found in considering several distinct, but related, interventions: transgenic 
upregulation of PGC-1α, AICAR (AMPK agonist), and GW501516 (PPARβ/δ agonist).   
Transgenic PGC-1α over-expression (22) and GW501516 (35) decreased eccentric injury, 
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however, AICAR (31) did not.  The increased fatigue resistance found in this study fits well 
with similar findings after PGC-1αgene transfer in neonates (52).   
Consistent with our hypothesis, utrophin gene and protein expression were increased 
in treated soleus muscles compared to control muscles.  Importantly, utrophin protein was 
located throughout the sarcolemma rather than just focused at the neuromuscular junction.  
Further, expression of agrin was increased in treated soleus muscles compared to control 
soleus muscles.  This potentially provides a secondary means of utrophin expression through 
an agrin/heregulin pathway (26, 35).  Associated with increased utrophin expression was 
increased expression of sarcoglycan and dystroglycan, genes whose protein products 
comprise important parts of the DAPC suggesting that utrophin is functioning as a dystrophin 
substitute. Of interest,  accumulation of dystroglycan, independent of other treatments, has 
also been shown to decrease disease severity in dystrophic skeletal muscle (34).  Improved 
resistance to damage caused by lengthening contractions indicates that the DAPC 
components are not only increased but also are functioning.  Indeed, numerous other 
investigations (i.e. 1, 41) have found that increased utrophin expression leads to increased 
expression and localization of DAPC components.  Increased expression of DAPC 
components may be directly or indirectly caused by PGC-1α gene transfer, but regardless, 
likely contributes to restoration of sarcolemma stability.   
 PGC-1α gene transfer was expected to lead to robust expression of genes associated 
with mitochondrial respiration, however, we found this response to be relatively modest.  
Expression of several oxidative signaling molecules was increased as expression of three 
AMPK subunits was increased approximately 50% and Pparg expression was nearly doubled.  
Consistent with these observations was increased citrate synthase expression, which would 
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allow increased TCA cycle activity.  Conversely, Gapdh expression was increased and 
expression of several oxidative genes was similar between groups (Table 2).  While the 
direction of change in gene expression was generally similar to previous investigations (40, 
59) the smaller magnitude of change is likely caused by the shorter duration of this study.  
Alternatively, it is possible that a rescue paradigm only partially restores metabolic function.  
Importantly though, the modest increase in oxidative genes translated into increased fatigue 
resistance in the PGC-1α expressing solei compared to control muscles.  
Contrary to our expectations, the percent of muscle fibers with centralized nuclei, a 
measure of muscle repair, was similar in treated and non-treated soleus muscles.  We 
anticipated that as PGC-1α pathway activation has been shown to increase utrophin 
expression and reduce muscle injury the need for repair would be decreased in PGC-1α over-
expressing limbs and be reflected in a lower degree of centralized nuclei.  Despite the clear 
reduction in muscle damage, demonstrated both histologically and functionally, central 
nucleation was similar between treated and control limbs.  Likewise, treatment with 
GW501516, a PPARβ/δ agonist, which, also lead to clear histological and functional 
benefits, did not result in reduction of central nucleation (35).  As both interventions used 
rescue as a model, as suggested by Miura et al. (35), the central nuclei in this investigation 
could have resulted from earlier damage and repair.  Considering that muscle injury would be 
predicted to be similar upon treatment, that damage was far less in the PGC-1α over-
expressing muscles following treatment, and centralized nucleation similar, an attractive 
alternative is a PGC-1α-mediated repair process.  Indeed, genes leading to increased satellite 
cell activation (Pax7), proliferation (Pax7, Ffg2, Bmp4), self-renewal (Myf5), and 
differentiation (Mef2c, Myf5 in the presence of MyoD) were increased in treated soleus 
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muscles compared to control (16, 42, 48, 50, 66, 67).  Further, PGC-1α has been shown to 
interact with and activate Mef2c (30).  This notion of a PGC-1α-mediated repair process is 
intriguing as the proliferative capacity of satellite cells appears to be limited with advanced 
disease in human patients (58).  Hence, a mechanism leading to increased muscle repair is of 
potential therapeutic importance.   
The role of autophagy in dystrophic skeletal muscle is an emerging area of focus as 
recent investigations have found that increased (12), not decreased (10), autophagy was 
associated with decreased disease-related injury.  That AICAR led to increased 
autophagy(43) raised the possibility that PGC-1α gene transfer might also perform a similar 
function.  Indeed, expression of Lc3 and Atg12, two key markers associated with autophagy, 
were induced by PGC-1α implicating another mechanism by which PGC-1α is decreasing 
disease-related muscle decline.   
While findings generally support a role for increased PGC-1α expression as a therapy 
for dystrophin-deficiency we also measured gene expression contrary to our expectations.  
For example, despite reduced immune cell infiltration we found evidence of increased Tnf 
signaling leading to cytokine production and increased expression of caspase 3 (38).  
Contrarily, we also found evidence of apoptosis resistance (Bcl2, αB crystalin) in soleus 
muscles over-expressing PGC-1α compared to contralateral limbs.  Further, augmented 
expression of calpains and atrogenes would suggest increased protein turnover in the PGC-1α 
treated limbs compared to control limbs, and may help to explain decreased muscle mass 
found in this investigation and others using a similar strategy (31, 52).  Conversely, in 
healthy muscle, transgenic over-expression of PGC-1α led to a reduction in expression of 
atrogenes after denervation or starvation (51).  The roles of inflammatory signaling, 
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apoptosis, and protein turnover are important considerations and will be addressed in future 
investigations  
 In summary, in this investigation we found that PGC-1α gene transfer rescued 
dystrophic muscle from disease-related decline suggesting that this strategy could be 
successful following diagnosis in human patients.   We found increased expression of 
utrophin and DAPC components, increased oxidative gene expression, and autophagy likely 
contributing to decreased muscle injury.  This was complemented by data pointing toward 
increased satellite cell activation indicating an elevated capacity for muscle repair.  Thus, 
PGC-1α leads to multiple mechanisms that synergistically act to decrease disease severity in 
dystrophin-deficient skeletal muscle.  Enthusiasm is dampened, however, as we also 
measured increased expression of atrogenes, genes involved in apoptotic signaling, and 
inflammation. Nevertheless, the successful interruption of the disease process through 
reduced muscle injury and improved muscle function points toward the therapeutic potential 
of this pathway.   
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Figure 1.  Disease related muscle injury in 3 week old mdx soleus muscle.  Following H&E 
staining, early signs of degeneration are apparent at three weeks of age in dystrophin-
deficiency soleus muscles.  400x  Scale bar = 50µm 
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Figure 2.  Gene transfer increases PGC-1α expression.  At three weeks of age mdx mice were 
injected in a single hind limb with a virus driving expression of PGC-1α and the contralateral 
hind limb was given an injection with null virus.  At six weeks of age soleus muscles were 
collected and PGC-1α expression measured by qPCR.  In treated limbs PGC-1α expression 
was 10.96 ± 3.1-fold greater than contralateral limbs.  n=8; * indicates significantly different 
from mdx-Null.  
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Figure 3 continued 
C. 
Immune Cell Infiltration
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Figure 3 continued 
E.   
H&E Negative Cells
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Figure 3 continued 
G. 
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Figure 3.  PGC-1α gene transfer decreases muscle injury.  Representative paired soleus 
muscle cross sections (mdx-Null - A; mdx-PGC-1α - B) stained with hematoxylin and eosin; 
100x. Scale bar indicates 100µm.  Areas of muscle injury were quantified and expressed 
relative to the total cross sectional area.  Areas of immune cell infiltration (green arrows; C), 
hypercontracted cells (blue arrows; D), and H&E negative cells (black arrows; E) were 
significantly reduced in PGC-1α over-expressing limbs as was the total damaged area (F).  
The percentage of fibers with centralized nuclei was similar between groups (G). n=9. * 
indicates significantly different from mdx-Null.   
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Figure 4.   
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Figure 4 continued 
C. 
Coefficient of Variation
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Figure 4.  Fiber size distribution.  Fiber size distribution of 6 wk old soleus muscle did not 
change following three weeks of PGC-1α gene transfer. Graphic representation of fiber size 
distribution (A).  Mean minimum Feret diameter (B) and the coefficient of variance (C) are 
similar in the PGC-1α overexpressing and control limb.  n=8. 
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Figure 5.   
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Figure 5.  Force following eccentric contractions.  Force decline following eccentric 
contractions was reduced by PGC-1α gene transfer.  Soleus muscles from 6 wk old mdx mice 
were exposed to 5 lengthening contractions three weeks following PGC-1α gene transfer.  
After all contractions the force produced by treated soleus muscles was higher compared to 
control * indicates significantly different from mdx-null; n=5. 
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Figure 6.   
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Figure 6. Fatigue resistance was improved by PGC-1α gene transfer.   
Soleus muscles from 6wk old mdx mice were tested for force production during repeated 
contractions (1/sec) three weeks following PGC-1α gene transfer.  The force produced by 
treated soleus muscles was is significantly higher than the force produced by the control 
soleus muscles throughout the experimental protocol.  n=6 
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Figure 7 continued 
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Figure 7.  Utrophin protein expression was increased by PGC-1α gene transfer.  Utrophin 
expression in paired 6 wk old mdx soleus muscles treated with either a null virus (A) or a 
virus driving PGC-1α expression (B) after 3 wks of gene transfer. 400x. Scale bar = 50µm.  
Within an animal, the replicate with the greatest expression from the control limb was 
compared to the replicate with the lowest expression from the treated limb (C).  n=3.  * 
indicates significantly different from mdx-Null.  
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Figure 8.   
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Figure 8.  Fold change of structural and sarcomeric genes altered by PGC-1α gene transfer.  
Gene expression was measured in 6 wk old soleus muscles from mdx mice three weeks 
following PGC-1α gene transfer.  n=6.  All genes are significantly different compared to 
control (p<0.05).  Fold change relative to mdx-Null. 
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Figure 9.  Fold change of metabolic genes altered by PGC-1α gene transfer.  Gene expression 
was measured in 6 wk old soleus muscles from mdx mice three weeks following PGC-1α 
gene transfer.  n=6.  All genes are significantly different compared to control (p<0.05).  Fold 
change relative to mdx-Null. 
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Figure 10. 
Satellite Cell Activation
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Figure 10.  Fold change of genes involved in satellite cell  activation that changed after PGC-
1α gene transfer.  Gene expression was measured in 6 wk old soleus muscles from mdx mice 
three weeks following PGC-1α gene transfer.  n=6.  All genes are significantly different 
compared to control (p<0.05).  Fold change relative to mdx-Null. 
 
Figure 11. 
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Figure 11.  Fold change of genes involved in protein turnover that changed after PGC-1α 
gene transfer.  Gene expression was measured in 6 wk old soleus muscles from mdx mice 
three weeks following PGC-1α gene transfer.  n=6.  All genes are significantly different 
compared to control (p<0.05).  Fold change relative to mdx-Null. 
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Figure 12 
Inflammation and Apoptosis
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Figure 12.  Fold change of inflammatory and apoptotic genes altered by PGC-1α gene 
transfer.  Gene expression was measured in 6 wk old soleus muscles from mdx mice three 
weeks following PGC-1α gene transfer.  n=6.  All genes are significantly different compared 
to control (p<0.05).  Fold change relative to mdx-Null. 
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Figure 13.  Fold change of autophagy genes altered by PGC-1α gene transfer.  Gene 
expression was measured in 6 wk old soleus muscles from mdx mice three weeks following 
PGC-1α gene transfer.  Fold change relative to mdx-Null.  n=6.* indicates significantly 
different from mdx-Null;  
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Table 1.  PGC-1α gene transfer did not improve cross sectional area CSA), tetanic force or 
specific tension in solei over-expressing PGC-1α compared to the contralateral control.  
n=11.  
 
 CSA (mm
2
) Tetanic Force (mN) Specific Tension (N/cm
2
) 
mdx-Null 0.75 ± 0.04 109 ± 8 14.6 ± 0.8 
mdx-PGC-1α 0.71 ± 0.03 104 ± 7 14.5 ± 0.6 
 
 
Table 2.  Genes that were similar between groups three weeks following PGC-1α gene 
transfer.  Three week old mdx mice were injected in a single hind limb with AAV driving 
PGC-1α expression and in the contralateral limb with an empty capsid. At 6wk of age gene 
expression was measured in soleus muscles.  n=6. Table arranged alphabetically by gene 
name.  Fold change relative to mdx-Null.  
 
Gene 
Abbreviation 
Fold 
Change 
p-
value 
Acta1 1.4 0.11 
Acvr2b 1.11 0.21 
Adipoq 2.81 0.06 
Atp2a1 1.36 0.06 
Camk2g 1.33 0.13 
Ctnnb1 1.19 0.2 
Dysf 1.05 0.85 
Dmpk 1.07 0.39 
Dmd 1.28 0.16 
Foxo1 1.42 0.11 
Foxo3 1.26 0.18 
Gusb 1.66 0.2 
Hk2 0.97 0.36 
Hdac5 1.27 0.27 
Igf1 1.97 0.06 
Lmna 1.1 0.47 
Lep 2.28 0.21 
Mmp9 2.46 0.27 
Mapk14 1.56 0.1 
Mapk3 1.38 0.1 
Musk 1.19 0.08 
Myod1 1.17 0.73 
Myf6 1.25 0.37 
Myog 1.76 0.22 
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Mb 1.1 0.42 
Myh2 1.1 0.52 
Mstn 2.33 0.28 
Neb 1.12 0.29 
Nos2 1.58 0.39 
Ppargc1a 1.22 0.24 
Ppargc1b 1.1 0.19 
Prkag1 1.18 0.44 
Pdk4 0.88 0.15 
Rhoa 1.72 0.07 
Slc2a4 1.04 0.17 
Akt1 1.3 0.15 
Ttn 0.96 0.17 
Tgfb1 1.94 0.22 
Tnnc1 1.34 0.27 
Tnnt1 1.13 0.28 
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CHAPTER 3.  MUSCLE FUNCTION IS IMPROVED IN DYSTROPHIC MUSCLE 
WITH PROLONGED DISEASE PROGRESSION AFTER PGC-1α GENE 
TRANSFER 
 
A paper to be submitted to the Journal of Applied Physiology 
 
Katrin Hollinger
1,2
, Joshua T. Selsby
2,3
 
Abstract 
 Duchenne muscular dystrophy (DMD) is a progressive and fatal muscle wasting 
disease caused by a dystrophin deficiency.  We previously found that gene transfer of PGC-
1α increased abundance of utrophin as well as increased mitochondrial biogenesis using 
prevention and rescue treatment paradigms.  Our purpose in this investigation was to 
determine the extent to which PGC-1α gene transfer would rescue dystrophic muscle 
following prolonged disease progression.  One year old mdx mice from our colony were 
injected in one hind limb with a virus driving expression of PGC-1α while the contralateral 
limb was injected with empty capsid.  Untreated C57 mice were included as an additional 
control.  Following three months of treatment viral gene transfer caused a 40-fold increase in 
PGC-1α expression compared to contralateral limbs.  Soleus muscles from mdx mice had a 
50% reduction in specific tension compared to C57 and over-expression of PGC-1α 
recovered 60% (p<0.05) of losses in addition to increasing resistance to fatigue compared to 
untreated muscles.  Force produced during the final contraction of the fatigue protocol was 
60% greater in treated soleus muscles than control (p<0.05).  Surprisingly, histopathology 
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was not improved by PGC-1α over-expression.  Also, while there were numerous differences 
in gene expression between healthy and dystrophic muscle there were relatively few between 
PGC-1α-treated limbs and contralateral controls.  These data indicate that PGC-1α pathway 
activation may interrupt the disease process even if initiated within the context of advanced 
disease, however, the mechanism that underlies this functional correction is not apparent.   
 
Key words: dystrophin, mdx, metabolism, inflammation, gene expression 
 
Introduction 
Duchenne muscular dystrophy (DMD) is an X-linked muscle wasting disease, caused 
by a mutation in the dystrophin gene (9).  In healthy muscle dystrophin is part of the 
dystroglycoprotein complex (DGC) and serves as a physical link from the intracellular 
environment to the extracellular environment.  This is accomplished by interacting with 
cytoskeletal f-actin on the C-terminus and directly with α-dystrobrevin and β-dystroglycan of 
the DGC on the N-terminus.  The DGC, in turn, connects to the extracellular matrix, which 
ultimately transmits forces to tendons and bones.  In dystrophic muscle there is a failure to 
accumulate dystrophin protein, which is necessary for DGC stability and assembly (10).  
This causes the sarcolemma to become more susceptible to lesions and loss of Ca
2+
 
homeostasis leading to mitochondrial dysfunction, and ultimately to myofiber necrosis (11, 
17).  The loss of myofibers due to necrosis and increased fibrosis results in a loss of whole 
muscle function (7, 18, 24).  This manifests clinically during the preschool years when 
parents notice boys suffer more frequent falls and fail to meet or maintain developmental 
milestones (9).  Because most patients are diagnosed due to muscle dysfunction it is clear 
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that disease-related damage to the muscles has already occurred.  Hence, successful 
treatments need to be able to halt disease progression within the intracellular environment of 
disease-related injury and even rescue severely damaged muscle from further decline.  
 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) 
over-expression can mitigate several of the secondary effects of dystrophin deficiency using 
both prevention and rescue paradigms (12-14, 22).  Specifically, we and others have shown 
that PGC-1α can lead to increased mitochondrial biogenesis and oxidative gene/protein 
expression and have also demonstrated increased autophagy during the initial necrotic bout 
experienced by hind limb muscles of mdx mice (12-14, 22).  This potentially allows non-
functional or dysfunctional mitochondria to be removed and replaced with new mitochondria, 
serving to alleviate some aspects of metabolic dysfunction.  We also observed a type I shift 
caused by PGC-1α gene transfer (22).  As part of the slow muscle program utrophin protein 
abundance was also increased and localized to the sarcolemma (13, 14, 22).  Utrophin is an 
autosomal dystrophin paralog and can substitute for dystrophin in the case of dystrophin 
deficiency and restore expression and localization of DGC components and sarcolemmal 
stability (27).  Also of import to dystrophic muscle, we demonstrated that PGC-1α gene 
transfer enhanced muscle repair using a rescue paradigm (14).  Collectively, PGC-1α leads to 
robust protection for dystrophic skeletal muscle.   
A limitation to this prior work, however, is that the beneficial effects of PGC-1α were 
either demonstrated in transgenic animals (13), used a disease prevention approach (22), or 
were focused on the initial bout of necrosis experienced by hind limb muscles from mdx 
mice (12, 14).  This is distinct from human patients whom are diagnosed following multiple 
bouts of degeneration and regeneration and disease that has advanced to the point of 
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impairing mobility.  Hence, the aim of this study was to determine the extent to which PGC-
1α gene transfer rescued dystrophic muscle from prolonged disease progression.  This is an 
important consideration in determining the therapeutic potential of this approach as well as 
optimizing the timing of clinical application. We hypothesize that PGC-1α gene delivery to 
dystrophic skeletal muscle which has experienced multiple cycles of degeneration and 
regeneration will have improved muscle function, reduced histopathology, and be more 
reminiscent of healthy muscle than untreated skeletal muscle from mdx mice.  
 
Material and Methods 
Animal Treatments.  All animal procedures were approved by the Institutional 
Animal Care and Use Committee at Iowa State University and were compliant with the 
practices established by the American Physiological Society.  Dystrophin-deficient mice 
(mdx mice) from our colony were aged for one year prior to treatment.  Mice were 
anesthetized with tribromoethanol and injected in the right hind limb with 7.5 x 10
11
 gc of 
adeno-associated virus (AAV) serotype 6, driving expression of peroxisome proliferator-
activated receptor-gamma co-activator -1alpha (PGC-1α).  Virus was delivered in a single 50 
μl bolus as we have done previously (14, 22), however, the injection was delivered to the 
mid-belly of triceps surae muscle group.  The left hind limb was injected with an equal 
volume of an AAV6 containing an empty capsid, and lacking a transgene.  Three months 
following viral injection mice were assigned to groups designated for measurement of muscle 
function or histology and biochemistry.  Tissue from healthy mice (C57) was also recovered 
and used for histological and biochemical measures.  Given the different groups used for 
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differing measures the number of samples used for a given measure are included in the figure 
legends.   
To collect tissues for histology and biochemistry mice were brought to a surgical 
level of anesthesia with tribromoethanol and soleus muscles and gastrocnemii were removed 
prior to sacrifice.  Soleus muscle pairs (treated limb and control limb from each animal) and 
C57 soleus muscles were used for histology and prepared as previously described (14).  To 
maximize information learned from each animal gastrocnemius muscles were designated for 
biochemistry and were snap frozen in liquid nitrogen.  An independent group of mdx mice 
was treated identically and shipped to the Physiological Assessment Core of the Wellstone 
Muscular Dystrophy Cooperative Center at the University of Pennsylvania so that soleus 
muscle function could be determined.  In pilot experiments we found that viral delivery in 
this fashion caused transgene expression in the triceps surae group (gastrocnemius and 
soleus) but not the muscles in the anterior compartment (tibialis anterior and extensor 
digitorum longus), hence, they were not included in this investigation.  We have found that 
viral delivery to neonates in the same fashion successfully delivered transgene to the muscles 
in the anterior and posterior compartment (22, 24).  Values for specific tension in the soleus 
from adult C57 (9-17 month) mice were taken from the literature (3, 15, 18, 25, 29). 
Histology.  Frozen soleus muscles were cut in 10 μm sections.  Hematoxylin and 
eosin staining was done according to standard techniques.  Sections were imaged at 100x 
magnification using an inverted Leica microscope and ImageQ software.   By acquiring 
overlapping images of the muscle sections we were able to reassemble the whole soleus 
section with the photomerge function in Photoshop.  Image analysis was performed on the 
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reconstructed images using OpenLab.  Data are presented as percent of damaged area relative 
to the total CSA. 
Immunohistochemisty (IHC) was done as previously described (14, 22). In short, 
sections were blocked with 5% BSA, incubated with primary antibody diluted in 5% BSA, 
and incubated at 4 °C overnight.  Secondary antibody was diluted in 5% BSA and incubated 
for one hour in the dark at room temperature.  Laminin (Neo Markers) and fibronectin 
(Sigma) were diluted at 1:100 and the corresponding secondary goat anti rabbit rhodamine 
conjugated (Millipore) and anti-rabbit Alexa Flour 488 conjugated (Cell Signaling 
Technology) were also diluted at 1:100.  Utrophin antibody was primary labeled with Alexa 
Flour 488 using the Zenon labeling kit (Invitrogen) as described by the manufacturer.  The 
labeled utrophin antibody was diluted 1:10 and incubated for 1 hour at room temperature in 
the dark.  Images were captured using an inverted fluorescent Leica microscope at 200x 
magnification.  Importantly, for a particular measure, all slides were treated identically and 
data were collected in paired samples in random order by a trained, blinded technician.  The 
fluorescent intensity was assessed using the density slice function in OpenLab as previously 
described (14). 
Function.  Animals designated for muscle function were shipped from Iowa State 
University to the Physiological Assessment Core of the Wellstone Muscular Dystrophy 
Cooperative Center at the University of Pennsylvania.  The soleus muscles were removed 
and stimulated according to standard techniques in order to measure tetanic tension, specific 
tension, and resistance to fatigue (2, 14, 19, 22-24).   
Biochemistry.  To better understand how PGC-1α may be altering the intracellular 
environment gastrocnemii were collected from the same animals used for histological 
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analysis.  Also, as we wanted to determine the degree of biochemical dysregulation caused 
by dystrophin deficiency and the degree of correction caused by PGC-1α over-expression, 
gastrocnemii were collected from a group of adult C57 mice.  Gastrocnemii were powdered 
with a dry ice chilled mortar and pestle.  Muscle was homogenized in Trizol (Invitrogen) for 
RNA extraction.  Briefly, the homogenate was centrifuged at 12,000xg for 10 min at 4 °C to 
remove insoluble materials.  Chloroform was added to the supernatant and phases were 
separated.  The aqueous phase (top phase) containing RNA was mixed with ethanol and 
applied to a column (Qiagen RNesay kit) where the samples were treated with Dnase (Qiagen 
Rneas free Dnase set) to prevent DNA contamination.  RNA concentrations were measured 
and quality assured using a Nanodrop (Thermo Scientific). 
Quantitative PCR.  cDNA was synthesized from 1 µg of RNA using a commercially 
available kit (QuantiTect Reverse Transcription Kit, Qiagen).  Gene expression was assessed 
following Fluidigm protocol B (Fast Gene Expression for Analysis Using EvaGreen). Briefly 
62.5 ng cDNA from each sample were pre-amplified with a pool of all primers used (Table 
1) and PreAmp master mix (Fluidigm).  Because such small volumes are used by the 
Fluidigm technology this pre-amplification step is recommended by Fluidigm to eliminate 
the possibility of sample bias. Unincorporated primers were removed with Exonuclease 1 
(New England BioLabs) and the pre-amplified samples were diluted 5-fold.  Samples were 
mixed with EvaGreen supermix with low ROX (Bio-Rad) and DNA Binding Dye 
(Fluidigm).  Sense and antisense primers were mixed with loading agent (Fluidigm) and the 
48.48 Dynamic Array IFC (Fluidigm) was primed followed by sample and array loading 
using an IFC controller MX (Fluidigm).  The prepared array was run in a BioMark HD 
(Fluidigm) using a GE 48x48 PCR+Melt plate and the v2.pcl program.  Data were analyzed 
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using the delta delta CT method (CTsample - CT18S = CT; CTcontrol limb -CTtreated limb = 
CT).  All statistical analyses were performed on the CT.  Data are shown as fold change 
relative to control (2^CT) as we have done previously (14). 
Statistics.  Functional changes were determined by comparing treated and 
contralateral mdx muscles with a paired T-test and changes in fatigue were determined using 
a 2-way ANOVA with repeated measures and sample pairing.  Changes in gene expression 
were determined by comparing delta CTs of treated, contralateral mdx muscle and healthy 
C57 with an ANOVA using MIXED procedure of SAS including animals as a random 
statement which allows for the mdx muscle to be paired within the analysis.  Histology and 
muscle weights were also analyzed in this fashion.  Statistical significance was considered 
p<0.05.  Data are shown as mean ± SEM unless otherwise noted.   
 
Results 
Viral gene transfer was used to achieve PGC-1α over-expression in the triceps surae 
of 1 year old mdx mice.  The one year old time point was chosen to evaluate the extent to 
which PGC-1α would rescue dystrophic muscle after repeated cycles of degeneratation and 
regeneration.  Mice were sacrificed three months after treatment.  At the time of tissue 
collection soleus mass was similar between treated limbs and control limbs.  Soleus muscle 
mass was significantly greater in mdx limbs, independent of treatment, compared to soleus 
muscles from C57 mice (mdx-Null 13.2± 0.6 mg; mdx- PGC-1α 13.4± 0.6 mg; C57 9.5± 0.5 
mg).  When normalized for body weight soleus mass was still greater in mdx mice compared 
to C57 (mdx-Null 0.39± 0.01 mg/g; mdx- PGC-1α 0.40± 0.02 mg/g; C57 0.29± 0.01 mg/g).  
Consistent with our previous work PGC-1α gene transfer caused a significant reduction in 
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gastrocnemius mass compared to contralateral controls and was also less than C57.  
Gastrocnemii from control limbs and from C57 animals were similar in mass (mdx-Null 
153.5± 5.5mg; mdx- PGC-1α 140.1± 5.7mg; C57 156.1± 6.2mg).  When normalized to body 
weight gastrocnemius mass was significantly reduced with PGC-1α gene transfer in the mdx 
mouse and the treated mdx gastrocnemius tended (p= 0.06) to have a reduced mass compared 
to healthy gastrocnemius muscles.  Relative mass of the gastrocnemius was similar between 
mdx and C57 mice (mdx-Null 4.6± 0.8mg/g; mdx- PGC-1α 4.2± 0.7mg/g; C57 4.8± 
0.2mg/g).   
In order to assess the functional benefits of PGC-1α over-expression in dystrophic 
muscle with advanced disease we evaluated muscle function in the soleus.  Cross sectional 
area (mdx-Null 1.8± 0.2 mm
2
; mdx- PGC-1α 1.6± 0.1 mm2) and tetanic force (mdx-Null 
178.8± 43.6 mN; mdx- PGC-1α 255.4± 16.0 mN) were similar between treated and control 
limbs.  Dystrophin deficiency caused an approximate 50% reduction in specific tension 
compared to mean reference values for healthy muscle (Figure 1).   PGC-1α gene transfer 
corrected 60% of this loss.  Further, soleus muscles over-expressing PGC-1α were 
approximately 40% more fatigue resistant than contralateral soleus muscles (Figure 1).   
To understand the composition of the muscle we performed hematoxylin and eosin 
staining on soleus muscle sections and the area of necrosis was measured.  The necrotic area 
was increased 80% (p<0.05) in soleus muscles taken from mdx mice compared to C57 
(Figure 2).  Soleus muscles from treated and untreated mdx limbs had similar amounts of 
necrotic area (Figure 2).  Also, the percent of muscle fibers with centralized nuclei was 
increased 84% (p<0.05) in soleus muscles from mdx mice compared to C57 (Figure 2) and 
was similar between both mdx limbs.  Fibrosis, measured with fibronectin IHC, was also 
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similar between treated and control mdx soleus muscles and was increased 2-fold (p<0.05) in 
mdx soleus muscles compared to C57 (Figure 3).  Fiber size distribution was similar between 
treated and control soleus muscles from mdx mice and both were different from C57, which 
was shifted toward the right (Figure 4).  Mean minimum feret diameter and coefficient of 
variance was similar between treated and control soleus muscles taken from mdx mice 
(Figure 4).  Mean diameter from soleus muscles taken from C57 mice was approximately 10 
µm larger (p<0.05) than soleus muscles taken from mdx mice and were 60% (p<0.05) less 
variable in distribution (Figure 4). 
To better understand dystrophic pathology and the mechanism by which PGC-1α 
conferred functional benefits to dystrophic muscle with advanced disease we used Fluidigm 
technology to probe pathways that PGC-1α had been previously shown to regulate using a 
rescue paradigm (Table 2).  As anticipated, there were numerous differences found when 
comparing dystrophic muscle to healthy muscle.  Consistent with previous reports of 
metabolic dysregulation, genes involved in mitochondrial biogenesis or function were 
decreased 75-85% in mdx compared to C57.  Genes involved in muscle repair and satellite 
cell function were decreased 45-75% in dystrophic muscle compared to healthy muscle.  
Autophagy-related genes were decreased 70-80% in mdx animals compared to healthy 
animals supporting previous reports of suppressed autophagy in dystrophic muscle (6, 21, 
26).  Also, antioxidant gene expression was decreased 75-90% in mdx mice compared to C57 
mice.  Surprisingly, genes involved in inflammatory singling were similar between C57 and 
mdx mice (Table2).   
Consistent with previous reports, PGC-1α gene abundance was decreased 80% 
(p<0.05) in untreated muscles from mdx mice compared to C57 (Table 2).  PGC-1α gene 
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transfer successfully increased PGC-1α mRNA abundance ~40-fold in the treated limb 
compared to the contralateral controls and 7-fold compared to C57.  Utrophin gene 
expression was decreased 50% at the 5' end and 75% at the 3' end of the transcript in 
untreated mdx muscle compared to C57.  PGC-1α gene transfer prevented the disease-
mediated reduction in utrophin expression at the 5' end of the transcript, however, at the 3′ 
end of the utrophin transcript the 75% reduction compared to healthy muscle persisted.  
Transcript abundance was similar at the 5' and 3' ends of the utrophin transcript between 
treated and control muscle from mdx mice.  These findings were confirmed with 
immunohistochemistry targeted to utrophin (Figure 5).   
Contrary to our previous findings using a rescue paradigm, expression of genes 
related to autophagy, redox balance, fiber type, and mitochondrial biogenesis were similar 
between treated and control limbs.  Embryonic myosin heavy chain was increased 2-fold in 
the PGC-1α overexpressing limb compared to healthy muscle, suggestive of increased repair, 
though other genes commonly associated with repair were similar between groups.  
Consistent with previous work using a rescue paradigm, genes related to inflammation were 
generally increased in PGC-1α-overexpressing limbs compared to contralateral controls.  
Specifically Il-1β was increased approximately ~2-fold, CD45, found on all macrophages, 
was increased 4-fold, and CD68, found in pro-inflammatory macrophages, was increased 2-
fold in PGC-1α over-expressing limbs compared to the contralateral limb.       
 
Discussion  
 Duchenne muscular dystrophy is caused by a mutation in the dystrophin gene 
resulting in production of a non-functional dystrophin protein, which leads to a host of 
88 
 
secondary affects, and ultimately to a loss of muscle function.  Because patients are 
diagnosed precisely because of impaired muscle function any successful therapy should be 
able to rescue muscle from further decline.  In a previous study we demonstrated that PGC-
1α gene transfer rescued muscle from further decline during the initial bout of necrosis (14).  
In the present investigation our purpose was to extend those previous observations and 
determine the extent to which PGC-1α gene transfer would rescue dystrophic muscle with 
prolonged disease progression.  We found that dystrophic muscle overexpressing PGC-1α 
had improved function compared to contralateral control muscle, however, histological 
measures were similar between groups.  Further, gene expression was largely unchanged by 
PGC-1α gene transfer.   
The increased muscle mass to body mass ratio found in dystrophic soleus muscles 
compared to healthy soleus muscles was similar to what has been reported by others (18).  It 
is likely that this increase in muscle mass is due to pseudohypertrophy, where the result is a 
larger, less functional muscle with accumulation of non-contractile material within the 
muscle cross section.  This is supported by our histological measures where increased 
damage is apparent in dystrophic muscle compared to healthy muscle.  This also helps to 
explain the reduction in specific tension observed when comparing healthy and dystrophic 
muscle in this and previous investigations (3, 15, 18, 25, 29).  The effects of PGC-1α gene 
transfer on soleus and gastrocnemius mass are in good agreement with previous work using a 
rescue paradigm (14).       
Troubling though is the role of PGC-1α over-expression as a tool to mitigate disease-
related injury in this investigation as we and others have shown consistent benefits using this 
strategy.  In the soleus muscle histological injury and mass were similar between treated and 
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untreated mdx limbs.  Also, abundance of genes previously shown or predicted to be altered 
by increased PGC-1α pathway activation was largely unchanged.  Despite that, specific 
tension was 60% greater and tetanic force was increased numerically by 40%, though failed 
to reach significance (p=0.09).  Also, the soleus muscles from the PGC-1α overexpressing 
limbs were more fatigue resistant compared to the contralateral limb.  Collectively, these 
functional benefits are in good agreement with previous findings using this approach while 
the failure to decrease histological injury and widely affect gene expression are decidedly not 
(14, 22).  When considered in aggregate, these data suggest that changes caused by PGC-1α 
following prolonged injury are operating at the intracellular level as at the whole muscle 
level histopathology is similar between treated and control limbs.   
As function was improved and whole muscle changes are not responsible it is 
reasonable to suggest intracellular mechanisms regulating force production are enhanced 
and/or protected following PGC-1α over-expression.  Speculatively, it seems likely that 
factors regulating excitation/contraction coupling are being affected as EC coupling is known 
to be dysregulated as a result of dystrophin deficiency (4, 5, 16) and a correction of 
excitation/contraction coupling would allow changes in force production (tetanic force, 
specific tension) or maintenance of force production (resistance to fatigue) without requisite 
histological changes.  Also, differing expression of myosin isoforms raises the possibility of 
simply having more cross bridges available for force production in PGC-1α over-expressing 
limbs compared to contralateral limbs.   
 As in our previous report using a rescue paradigm, PGC-1α gene transfer increased 
inflammatory signaling.  Consistent with these observations, TNF transcript abundance was 
increased in healthy mice with transgenic PGC-1α over-expression (20).  Previous work in 
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cardiac muscle cells shows that NF-κB can bind to PGC-1α and lead to the degradation of 
PGC-1α (1).  While this interaction serves to negatively regulate PGC-1α it does not prevent 
NF-κB from transcriptionally activating its targets.  Hence, it is plausible that NF- κB-
mediated suppression of PGC-1α pathway activity prevented the robust response anticipated 
in gene expression while simultaneously increasing gene abundance associated with Nf-κB 
activity.  That increased inflammatory signaling is observed in multiple studies suggests the 
possibility of increased NF-κB pathway activity as a direct result of increased PGC-1α 
pathway activity.  Indeed, PGC-1α over-expression has been shown to activate NF-κB by 
phosphorylation (20).  While our data do support this sort of interaction there are conflicting 
reports that indicate suppressed NF-κB pathway activation with increased PGC-1α 
expression (8, 28).    
Changes in gene abundance between healthy and dystrophic muscle were generally in 
good agreement with previous findings in muscle that has experienced previous cycles of 
degeneration and regeneration.  For example, of emerging interest, we report suppressed 
expression of genes associated with autophagy in dystrophic muscle compared to healthy 
muscle, which is consistent with recent findings (6, 21, 26).  Surprisingly though, PGC-1α-
mediated rescue of muscle with advanced disease did not alter gene abundance related to 
autophagy or a variety of other processes in contrast to rescue targeted toward early disease 
(14).  It seems likely that this is indicative of fundamental differences between acute and 
chronic disease-related injury.     
 In summary, PGC-1α gene transfer in dystrophic muscle with prolonged disease 
progression caused functional improvements, however, histopathology and gene expression 
were largely unchanged.  We conclude that PGC-1α pathway activation is a good therapeutic 
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strategy for dystrophic muscle, however, the mechanism that limits correction to function and 
excludes histopathology and gene expression is unclear.  Given this, it now appears that a 
more robust response will be gained by initiating this approach at the earliest possible time.  
Also, these data contribute to the notion that there are fundamental differences in dystrophic 
muscle early in progression and with more advanced disease, which may necessitate stage-
specific interventions in order to maximize beneficial outcomes.     
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Figure 1.  PGC-1α improves muscle function in dystrophic muscle from 15 month old mice.  
(A) Dystrophin deficiency decreased specific tension by 50% compared to reference values 
for healthy adult muscle obtained from the literature (3, 15, 18, 25, 29).  One value is shown 
as a square as this value was recently reported by the same lab as where muscle function in 
this investigation was measured.  PGC-1α gene transfer to 12 month old mdx mice led to a 
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60% recovery of specific tension compared to the contralateral limb.  (B) PGC-1α over-
expression improved fatigue resistance compared to contralateral soleus muscles.    
n=4/group; * indicates significantly different from mdx-Null: * - p<0.05, ** - p<0.001, *** - 
p<0.0001.    
Figure 2. 
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Figure 1 continued 
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Figure 2 continued  
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Figure 2.  Independent of treatment Dystrophic muscle has severe histopathology compared 
to healthy muscle.  Representative H&E images of C57 (A), mdx-Null (B) and the 
corresponding PGC-1α over-expressing limb (C).  (D) Necrotic area was quantified and 
expressed relative to the total section area.  Dystrophin deficiency caused an increase in 
necrotic area that was not decreased by PGC-1α gene transfer.  (E) Centralized nuclei were 
also increased in dystrophic muscle independent of treatment.  mdx n=8/group, C57 n=2; * 
indicates significantly different from mdx-Null: * - p<0.05, ** - p<0.001, *** - p<0.0001.    
 # indicates significantly different from C57: # - p<0.05, ## - p<0.001, ### - p<0.0001.    
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Figure 3 continued 
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Figure 3.  Fibrosis is reduced in healthy muscle compared to dystrophic muscle.  
Representative IHC images of fibronectin from soleus muscles from C57 (A) mdx-Null (B) 
and mdx-PGC-1α (C).  Fibronection is stained green and nuclei are counterstained with 
DAPI (blue).  Quantification of fibronectin fluorescence shows increased fibrosis in 
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dystrophic muscle compared to healthy (D).  PGC-1α gene transfer did not decrease fibrosis.  
mdx n=8/group. C57 n=2; * indicates significantly different from mdx-Null: * - p<0.05, ** - 
p<0.001, *** - p<0.0001.  # indicates significantly different from C57: # - p<0.05, ## - 
p<0.001, ### - p<0.0001.    
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Figure 4 continued 
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Figure 4.  Fiber size is altered by dystrophin deficiency.  Fiber diameter distribution is shifted 
toward larger fibers in C57 compared to mdx and PGC-1α over-expression did not alter this 
effect (A). Mean fiber diameter is 10 µm larger (B) in healthy muscle compared to 
dystrophic muscle and is also less variable (C).  mdx n=10/group, C57 n=2; * indicates 
significantly different from mdx-Null: * - p<0.05, ** - p<0.001, *** - p<0.0001.  # indicates 
significantly different from C57: # - p<0.05, ## - p<0.001, ### - p<0.0001.    
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Figure 5 continued  
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Figure 5.  Utrophin protein abundance in dystrophic muscle is similar to dystrophic muscle 
overexpressing PGC-1α.  Representative IHC images (mdx-Null (A) and mdx-PGC-1α (B)) 
and quantification (C) of fluorescent signal.   n=9/group.    
 
Table 1.  Primer sequences used for Fluidigm qPCR.  
Gene name   Sequence 
sirtuin 1 
Forward AGTTCCAGCCGTCTCTGTGT 
Reverse CTCCACGAACAGCTTCACAA 
peroxisome proliferator-activated 
receptor gamma, coactivator 1 
alpha 
Forward ATGTGTCGCCTTCTTGCTCT 
Reverse ATCTACTGCCTGGGGACCTT 
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Mitochondrial biogenesis 
  
estrogen-related receptor alpha 
Forward CCAGGCTTCTCCTCACTGTC 
Reverse GCCCCCTCTTCATCTAGGAC 
 
Table 1 continued 
 
nuclear respiratory factor 1 
Forward GCACCTTTGGAGAATGTGGT 
Reverse CTGAGCCTGGGTCATTTTGT 
transcription factor A, 
mitochondrial 
Forward CCAAAAAGACCTCGTTCAGC 
Reverse CTTCAGCCATCTGCTCTTCC 
transcription factor B1, 
mitochondrial 
Forward CTCCTGGACTTGAGGCTGAC 
Reverse AACCCTGGGATAAAGCGAGT 
transcription factor B2, 
mitochondrial 
Forward TAGAGCCGTTGCCTGATTCT 
Reverse TAATGCCCCAGTCAGGATTC 
ubiquinol-cytochrome c reductase 
core protein I 
Forward GACAACGTGACCCTCCAAGT 
Reverse ACTGGTACATAGGCGCATCC 
mitochondrial encoded cytochrome 
c oxidase II 
Forward CCAAATCTCCACGGTCTGTT 
Reverse GTCTGCCCTTTCTCCCTTCT 
   
Metabolism 
  
phosphofructokinase, muscle 
Forward GCTGTGGTCCGAGTTGGTAT 
Reverse CTCTCGGAAGTCCTTGCATC 
citrate synthase 
Forward GTTGGCAAAGACGTGTCAGA 
Reverse CTTGTACAGCTGAGCCACCA 
myoglobin 
Forward CCTGGGTACCATCCTGAAGA 
Reverse GAGCATCTGCTCCAAAGTCC 
glyceraldehyde-3-phosphate 
dehydrogenase 
Forward ACTCCACTCACGGCAAATTC 
Reverse TCTCCATGGTGGTGAAGACA 
creatine kinase, muscle 
Forward CATGGAGAAGGGAGGCAATA 
Reverse GACGAAGGCGAGTGAGAATC 
adenylate kinase 1 (myokinase) 
Forward TGGATTCTTCCAATGGCTTC 
Reverse CGCTTCTTGATGGTCTCCTC 
   
Slow muscle program 
  
GA binding protein transcription 
factor, alpha 
Forward GGGGAACAGAACAGGAAACA 
Reverse CCGTAATGCACGGCTAAGTT 
utrophin 5′ 
Forward GTTTGAGGTGCTTCCTCAGC 
Reverse GCGATATCTGGTAGCTGTCC 
utrophin 3′ 
Forward CGACAACATCTGGGGAAGAT 
Reverse GTGCTCTGGCCACATACTGA 
myosin, heavy chain 7 (type I) Forward AGATGAATGCCGAGCTCACT 
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Reverse CTCATCCAAACCAGCCATCT 
myosin, heavy chain 2 (type IIa) 
Forward GAGCAAAGATGCAGGGAAAG 
Reverse TAAGGGTTGACGGTGACACA 
 
Table 1 continued 
 
myosin, heavy chain 2 (type IIx) 
Forward AGAAGCTCCTGGGATCCATT 
Reverse CTCTCGCCAAGTACCCTCTG 
myosin, heavy chain 2 (type IIb) 
Forward GGGGCTGTACCAGAAATCCG 
Reverse CCTGAAGAGAGCTGACACGG 
   
Repair/ satellite cell 
  
paired box 7 
Forward GACTCCGGATGTGGAGAAAA 
Reverse GAGCACTCGGCTAATCGAAC 
myocyte enhancer factor 2C 
Forward CACTAGCACTCATTTATCTC 
Reverse ACAGCTGCTCAAGCTGTCAA 
myogenic factor 5 
Forward TGAGGGAACAGGTGGAGAAC 
Reverse AGCTGGACACGGAGCTTTTA 
myogenin (myogenic factor 4) 
Forward TCCAGTACATTGAGCGCCTA 
Reverse ACGATGGACGTAAGGGAGTG 
myosin, heavy chain 3, embryonic 
Forward ACGACAACTCGTCTCGCTTT 
Reverse TTGGTCGTAATCAGCAGCAG 
   
Autophagy 
  
microtubule-associated protein 1 
light chain 3 alpha 
Forward GATAATCAGACGGCGCTTGC 
Reverse ACTTCGGAGATGGGAGTGGA 
autophagy related 12 
Forward TCCTTAAACTGGTGGCCTCG 
Reverse TGCAGTAATGCAGGACCAGT 
BCL2/adenovirus E1B 19kDa 
interacting protein 3 
Forward TTCTCACTGTGACAGCCCAC 
Reverse ATGCTGAGAGTAGCTGTGCG 
GABA(A) receptor-associated 
protein like 1 
Forward GGTCATCGTGGAGAAGGCTC 
Reverse GGAGGGCACAAGGTACTTCC 
   
Inflammation 
  
interleukin 6 (interferon, beta 2) 
Forward CTGATGCTGGTGACAACCAC 
Reverse CAGAATTGCCATTGCACAAC 
interleukin 1, beta 
Forward GGGCCTCAAAGGAAAGAATC 
Reverse TACCAGTTGGGGAACTCTGC 
protein tyrosine phosphatase, 
receptor type, C 
Forward CCTGCTCCTCAAACTTCGAC 
Reverse GACACCTCTGTCGCCTTAGC 
CD68 molecule Forward CCAATTCAGGGTGGAAGAAA 
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Reverse CTCGGGCTCTGATGTAGGTC 
CD163 molecule 
Forward TGGTGTGCAGGGAATTACAA 
Reverse ATCCCTGCTGTGGGTACAAG 
 
Table 1 continued 
 
Antioxidant response   
catalase 
Forward ACATGGTCTGGGACTTCTGG 
Reverse CAAGTTTTTGATGCCCTGGT 
superoxide dismutase 1, soluble 
Forward CCAGTGCAGGACCTCATTTT 
Reverse TTGTTTCTCATGGACCACCA 
superoxide dismutase 2, 
mitochondrial 
Forward CCGAGGAGAAGTACCACGAG 
Reverse GCTTGATAGCCTCCAGCAAC 
   
Other 
  
heat shock 70kDa protein 1A 
Forward CGAGGCTGACAAGAAGAAGG 
Reverse CTGGTACAGCCCACTGATGA 
heat shock 27kDa protein 1 
Forward GAAGAAAGGCAGGACGAACA 
Reverse CTCAGGGGATAGGGAAGAGG 
18S 
Forward 
GGGAGGTAGTGACGAAAAATA 
ACAAT 
Reverse TTGCCCTCCAATGGATCCT 
 
 
Table 2.  Gene expression is altered by dystrophin deficiency and overexpression of PGC-1α.  
Relative gene abundance was measured using the Fluidigm technology, which allowed us to 
compare gene expression from gastrocnemius taken from healthy adult muscle, dystrophic 
muscle, and dystrophic muscle overexpressing PGC-1α.  mdx n=11/group, C57 n=10.  * 
indicates significantly different from mdx-Null: * - p<0.05, ** - p<0.001, *** - p<0.0001.  # 
indicates significantly different from C57: # - p<0.05, ## - p<0.001, ### - p<0.0001.    
 
Gene name Abbreviation  
C57        
fold-
change 
mdx-
Null  
fold-
change 
  
mdx-
PGC1α  
fold-
change 
 
sirtuin 1 Sirt1 
1.00± 
0.13 
0.15± 
0.04 
##
# 
0.20± 
0.04 
## 
peroxisome proliferator-
activated receptor 
gamma, coactivator 1 
alpha 
 
Ppargc1a (Pgc-
1α) 
1.00± 
0.17 
0.19± 
0.05 
##
# 
7.06± 
1.57 
###**
* 
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Mitochondrial 
biogenesis       
estrogen-related receptor 
alpha 
Esrra 
1.00± 
0.14 
0.28± 
0.06 
## 
0.22± 
0.03 
## 
nuclear respiratory factor 
1 
Nrf1 
1.00± 
0.12 
0.28± 
0.07 
## 
0.36± 
0.05 
# 
transcription factor A, 
mitochondrial 
Tfam 
1.00± 
0.08 
0.20± 
0.04 
##
# 
0.19 ± 
0.04 
### 
transcription factor B1, 
mitochondrial 
Tfb1m 
1.00± 
0.08 
0.16± 
0.03 
##
# 
0.17 ± 
0.03 
### 
transcription factor B2, 
mitochondrial 
Tfb2m 
1.00± 
0.07 
0.16± 
0.03 
##
# 
0.13± 
0.03 
### 
ubiquinol-cytochrome c 
reductase core protein I 
Uqcrc1 
1.00± 
0.10 
0.18± 
0.04 
##
# 
0.14± 
0.03 
### 
mitochondrially encoded 
cytochrome c oxidase II 
mt-Co2 
1.00± 
0.07 
0.27± 
0.04 
##
# 
0.23± 
0.04 
### 
       
Metabolism 
      
phosphofructokinase, 
muscle 
Pfkm 
1.00± 
0.10 
0.19± 
0.03 
##
# 
0.15± 
0.03 
### 
citrate synthase Cs 
1.00± 
0.11 
0.21± 
0.03 
##
# 
0.17± 
0.03 
### 
myoglobin Mb 
1.00± 
0.08 
0.24± 
0.06 
##
# 
0.19± 
0.03 
### 
glyceraldehyde-3-
phosphate 
dehydrogenase 
Gapdh 
1.00± 
0.12 
0.18± 
0.03 
##
# 
0.16± 
0.03 
### 
creatine kinase, muscle Ckm 
1.00± 
0.06 
0.22± 
0.05 
##
# 
0.18± 
0.03 
### 
adenylate kinase 1 
(myokinase) 
Ak1 
1.00± 
0.11 
0.17± 
0.05 
##
# 
0.12± 
0.03 
### 
       
Slow muscle program 
      
GA binding protein 
transcription factor, 
alpha 
Gabpa (Nrf2) 
1.00± 
0.11 
0.25± 
0.05  
0.26± 
0.04 
### 
utrophin 5′ Utrn 
1.00± 
0.18 
0.50± 
0.10 
# 
0.63± 
0.07  
utrophin 3′ Utrn 
1.00± 
0.19 
0.25± 
0.05 
## 
0.26± 
0.04 
## 
myosin, heavy chain 7 
(type I) 
Mhy7 
1.00± 
0.32 
0.33± 
0.05 
# 
0.27± 
0.04 
# 
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myosin, heavy chain 2 
(type IIa) 
Mhy2 
1.00± 
0.20 
0.10± 
0.02 
##
# 
0.09± 
0.02 
### 
myosin, heavy chain 2 
(type IIx) 
Mhy1 
1.00± 
0.15 
0.26± 
0.05 
## 
0.22± 
0.04 
## 
myosin, heavy chain 2 
(type IIb) 
Mhy4 
1.00± 
0.11 
0.14± 
0.04 
##
# 
0.08± 
0.02 
### 
       
Repair/ satellite cell 
      
paired box 7 Pax7 
1.00± 
0.24 
0.55± 
0.09  
0.43± 
0.08 
# 
myocyte enhancer factor 
2C 
Mef2c 
1.00± 
0.15 
0.26± 
0.07 
## 
0.17± 
0.03 
## 
myogenic factor 5 Myf5 
1.00± 
0.11 
0.25± 
0.06 
## 
0.25± 
0.06 
## 
myogenin (myogenic 
factor 4) 
Myog 
1.00± 
0.21 
0.38± 
0.11 
# 
0.82± 
0.20  
myosin, heavy chain 3, 
embryonic 
Mhy3 
1.00± 
0.25 
1.67± 
0.32  
2.14± 
0.32 
## 
       
Autophagy 
      
microtubule-associated 
protein 1 light chain 3 
alpha 
Map1lc3a (Lc3) 
1.00± 
0.05 
0.28± 
0.04 
##
# 
0.27± 
0.05 
### 
autophagy related 12 Atg12 
1.00± 
0.08 
0.20± 
0.03 
##
# 
0.24± 
0.03 
### 
BCL2/adenovirus E1B 
19kDa interacting 
protein 3 
Bnip3 
1.00± 
0.09 
0.21± 
0.04 
## 
0.21± 
0.05 
## 
GABA(A) receptor-
associated protein like 1 
Gabarapl1 
1.00± 
0.09 
0.22± 
0.04 
# 
0.26± 
0.04 
# 
       
Inflammation 
      
interleukin 6 (interferon, 
beta 2) 
Il6 
1.00± 
0.24 
0.76± 
0.33  
0.42± 
0.12  
interleukin 1, beta Il1b 
1.00± 
0.47 
2.20± 
1.01  
4.71± 
1.09 
#** 
protein tyrosine 
phosphatase, receptor 
type, C 
Ptprc (Cd45) 
1.00± 
0.28 
1.82± 
1.02  
7.56± 
1.28 
##*** 
CD68 molecule Cd68 
1.00± 
0.28 
0.75± 
0.27  
1.48± 
0.29 
** 
CD163 molecule Cd163 
1.00± 
0.18 
0.71± 
0.17  
0.82± 
0.13  
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Antioxidant response 
      
catalase Cat 
1.00± 
0.16 
0.10± 
0.02 
##
# 
0.10± 
0.02 
### 
superoxide dismutase 1, 
soluble 
Sod1 
1.00± 
0.10 
0.27± 
0.05 
##
# 
0.29± 
0.05 
## 
superoxide dismutase 2, 
mitochondrial 
Sod2 
1.00± 
0.08 
0.24± 
0.04 
##
# 
0.19± 
0.03 
### 
       
Other 
      
heat shock 70kDa 
protein 1A 
Hspa1a 
1.00± 
0.12 
0.19± 
0.04 
## 
0.23± 
0.05 
## 
heat shock 27kDa 
protein 1 
Hspb1 
1.00± 
0.09 
0.23± 
0.05 
## 
0.31± 
0.06 
## 
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CHAPTER 4.  LONG-TERM QUERCETIN DIETARY ENRICHMENT DECREASES 
MUSCLE INJURY IN MDX MICE 
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Non-standard abbreviations 
PGC-1α  peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(Ppargc1a) DMD  Duchenne muscular dystrophy  
DGC dystrophin-glycoprotien complex  
 
Abstract 
Background & Aims:  Duchenne muscular dystrophy results from a mutation in the 
dystrophin gene, which leads to a dystrophin-deficiency.  Dystrophic muscle is marked by 
progressive muscle injury and loss of muscle fibers.  Activation of the PGC-1α pathway has 
been previously shown to decrease disease-related muscle damage.  Oral administration of 
the flavonol, quercetin, appears to be an effective and safe method to activate the PGC-1α 
pathway.  The aim of this investigation was to determine the extent to which long term 
dietary quercetin enrichment would decrease muscle injury in dystrophic skeletal muscle.  
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We hypothesized that quercetin would rescue dystrophic muscle from further decline by 
activation of the PGC-1 α pathway. 
Methods:  Beginning at three-months of age and continuing to nine-months of age mdx mice 
(n=10/group) were assigned to either to mdx-control receiving standard chow or to mdx-
quercetin receiving a 0.2% quercetin-enriched diet.  At nine-months of age mice were 
sacrificed and costal diaphragms collected.  One hemidiaphragm was used for histological 
analysis and the second hemidiaphragm was used to determine gene expression via RT-
qPCR.  
Results:  The diaphragm from the mdx-quercetin group had 24% (p≤0.05) more muscle 
fibers/area and 34% (p≤0.05) fewer centrally nucleated fibers compared to the mdx-control 
group.  Further, there were 44% (p≤0.05) fewer infiltrating immune cells/area, a 
corresponding 31% (p≤0.05) reduction in TNF gene expression, and a near 50% reduction in 
fibrosis.  The quercetin-enriched diet increased expression of genes associated with oxidative 
metabolism but did not increase utrophin protein abundance.  
Conclusions:  Long-term quercetin supplementation decreased disease-related muscle injury 
in dystrophic skeletal muscle, however the role of PGC-1α pathway activation as a mediator 
of this response is unclear.   
 
Keywords: Duchenne muscular dystrophy, PGC-1α, resveratrol, dystrophin, diaphragm  
 
Introduction 
Duchenne muscular dystrophy (DMD) is caused by dystrophin protein deficiency.  
Dystrophin serves as a link between the actin cytoskeleton and the extracellular matrix 
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through the dystrophin-glycoprotien complex (DGC) (1).  DMD is marked by loss of muscle 
function resulting in wheelchair confinement and death due to respiratory or cardiac failure 
generally in the third decade of life (2).  This disease is modeled by the mdx mouse.  The 
diaphragm of the mdx mouse most accurately recapitulates disease progression (3).  
 Transgenic over-expression and neonatal gene delivery of peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (Ppargc1a; PGC-1α) prevented or delayed 
disease onset (4, 5) and gene delivery also rescued actively declining skeletal muscle (6).  
Nutraceutical-mediated activation of the PGC-1α pathway could make this approach 
translatable to DMD patients.  Resveratrol, a polyphenol, is thought to be a PGC-1α activator 
via Sirtuin-1 (Sirt1) (7) or AMPK (8).  Because of the equivocal results (4, 7, 9, 10) and 
significant safety concerns (4) with resveratrol we sought out a compound that could drive 
the PGC-1α pathway, be rapidly administered to the DMD population, and had an excellent 
safety profile.  Quercetin, a flavonol, met all of these requirements.   
Quercetin is a potent Sirt1 activator (11) capable of entering muscle cells following 
oral delivery (12, 13), which can lead to PGC-1α deacetylation and subsequent 
activation(14). Importantly, oral administration of quercetin to sedentary humans (15) and 
mice (14) increased mRNA and protein abundance of Sirt1 and PGC-1α and induced 
mitochondrial biogenesis in skeletal muscle.  Quercetin may be beneficial to dystrophic 
skeletal muscle because of cellular pathway activation and/or through independent secondary 
effects including antioxidant and anti-inflammatory functions (16, 17).  Also, quercetin is 
safe at high-dose (up to 12,000 mg/kg/day) for up to two years (18-22).  Therefore, the 
purpose of this investigation was to determine the extent to which long-term dietary 
quercetin enrichment would decrease injury in dystrophic skeletal muscle.  We hypothesized 
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that quercetin would rescue declining dystrophic skeletal muscle and increase utrophin 
abundance without causing obvious toxicities.   
 
Methods 
Animal Treatments.  All animal procedures were approved by the IACUC at Iowa 
State University and were done in accordance with the guiding principles established by the 
American Physiological Society.  At three-months of age 20 mdx mice were randomly 
divided in two groups receiving either standard chow (BioServe, Rodent diet) or standard 
diet enriched with 0.2% quercetin (BioServe, Rodent diet + 0.2% quercetin) for six months.  
During the study period mice were weighed weekly and food consumption was recorded 
biweekly.  At nine-months of age mice were anesthetized to a surgical plane with 
tribromoethanol, sacrificed by cervical dislocation, and the costal diaphragm removed and 
divided into hemidiaphragms.  One hemidiaphragm was snap frozen in liquid nitrogen for 
measures of gene expression and the other was coated in freezing media and frozen for 
histological analyses. 
Histology.  Ten-micron frozen sections were cut from the diaphragm and placed on 
slides.  Hematoxylin and Eosin staining was performed according to standard techniques.  
Each diaphragm section was visualized using a Leica microscope at 100x and 2-4 images 
were taken of each diaphragm.  Following a cursory inspection of slides from each group we 
hypothesized that diaphragms from quercetin treated animals had a greater abundance of 
muscle fibers compared to control fed mice.  Using ImageJ (23) the total number of skeletal 
muscle fibers and the number of skeletal muscle fibers with a centralized nucleus were 
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counted in two images/section (77-330 fibers/image).  Data are reported as the average (± 
SEM) of these two images.    
To identify utrophin protein localization and abundance, utrophin antibody ((1:10 
dilution, Vector VP-U579) directly labeled with Zeon Alexa 568 (Invitrogen Z25006) was 
used as previously described (6).  To evaluate fibronectin abundance, an indicator of fibrosis, 
sections were first blocked with 5% BSA.  Sections were incubated with anti-fibronectin 
antibody ((1:100, Sigma F3648) at 4°C overnight.  The next day slides were washed three 
times with PBS.  Following the wash, sections were incubated with fluorescein conjugated 
goat anti-mouse IgG at (1:100; Millipore) for 1 h in the dark.  After the incubation period 
slides were washed three times in PBS and then cover slips were applied and sealed.  To 
visualize fibronectin abundance for each section 1-3 non-overlapping 200x images were 
taken under identical exposure conditions.  To quantify protein abundance IHC images were 
converted into binary images using OpenLab (version 3.5.1, Perkin Elmer) as previously 
described (6).   
Determination of fiber type differences by IHC was done in two serial sections. 
Sections were washed and blocked as described for fibronection.  One section was incubated 
with primary antibody for  MhcI (A4.951, Hybridoma Bank University of Iowa developed by 
Blau, H.M.) and laminin (NeoMarkers, RB-082-A) the second section was incubated with 
primary antibody for MhcIIa (SC-71, Hybridoma Bank University of Iowa developed by 
Schiaffino, S.) and laminin.  Primary myosin antibodies were detected using fluorescein 
conjugated goat anti-mouse IgG at 1:100 (Millipore, 12-506) and laminin was detected with 
goat anti-rabbit rhodamine conjugated IgG (Millipore, 12-510), respectively.  Slides were 
imaged at 200x at the same area in both serial sections. For analyses, both the total number of 
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cells/image and the number of positive staining cells/image were counted using Image J (23).  
Cells that were negative for MhcI and MhcIIA were consider MhcII x/b and cells that were 
positive with both myosin antibodies were consider MhcI/IIa fibers. .  The cell counts from 
2-3 images/section were pooled, resulting in approximately 100-400 cells/section.   
Biochemistry.  RNA was extracted from the remaining hemidiaphragm using Trizol 
according to manufacturer recommendations (Invitrogen, 15596-018).  To eliminate organic 
carryover and DNA contamination RNA was purified using a Qiagen RNesay spin column 
(Qiagen RNeasy Mini Kit, 74106) in combination with an on-column DNase (Qiagen RNase 
free DNase set, 79254) treatment.  RNA concentration was measured using a Nanodrop 
(Thermo Scientific).  From 1µg RNA, cDNA was synthesized following manufacturer’s 
instructions (QuantiTect Reverse Transcription Kit, Qiagen 205311) with the addition of 18S 
RT primers.  To measure expression of genes of interest QuantiFast SYBR Green PCR kit 
(Qiagen, 204056), primers (Table 1) and 10 ng of cDNA template, were loaded into each 
well for a total 12.5 µL reaction volume.  Gene expression was assayed with a Mastercycler 
EP Realplex (Eppendorf).  All samples were measured in triplicate wells and normalized to 
18S expression calculating  the delta CT (dCT) values.  dCT values were calculated by 
subtracting the 18S CT value from the CT value for the gene of interest.  ddCT was 
calculated by subtraction of the highest dCT of a given gene from all the dCT for that gene.   
Statistics.  For body weight and food consumption control and quercetin treated 
animals were compared with an ANOVA with repeated measures.  All other data from 
control and quercetin-treated mdx mice were compared using a Student’s-test.  For gene 
expression statistics were performed on the dCT. Gene expression data are presented as fold 
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change as calculated from ddCT.  Significance was set at p≤0.05.  All data are expressed as 
means ± SEM unless otherwise noted.   
 
Results  
Three-month old mdx mice were fed a control or 0.2% quercetin-enriched diet for six 
months.  The body mass of the mice in both groups increased as they aged (p≤0.05) but did 
not differ between groups (Figure 1).  Likewise, food consumption increased throughout the 
study period (p≤0.05) similarly in both groups (Figure 1).  Upon sacrifice at nine-months of 
age, mice on the control diet weighed 31.4 ±1.3 g and mice on the quercetin-enriched diet 
weighed 29.5 ± 1.0 g.  Gastrocnemius mass was similar between groups when considered as 
absolute mass (mdx-Con - 172± 9 mg; mdx-Q - 157± 8 mg) or normalized to body weight 
(mdx-Con - 5.5± 0.1 mg/g; mdx-Q - 5.3± 0.1 mg/g).  In addition to normal growth, food 
consumption, and muscle mass, mice treated with the quercetin-enriched diet did not exhibit 
obvious signs of toxicity including failure to groom, lethargy, or death. 
To determine the extent to which the quercetin-enriched diet protected dystrophic 
skeletal muscle we performed a histological evaluation of the diaphragms.  Following H&E 
staining, the diaphragm sections from the quercetin-treated mdx mice exhibited less disease-
related injury and appeared healthier than the diaphragm sections from the control-treated 
mice (Figure 2).  To objectively quantify histological changes we measured the number of 
muscle fibers, percent of fibers with centralized nuclei, and fibrotic area. Diaphragms from 
quercetin-treated mice had 24% (p≤0.05) more muscle fibers/area than diaphragms from 
control-treated mice (Figure 2).  Further, there was a 34% decrease in fibers with centralized 
nuclei (Figure 2).  Because the quercetin-enriched diet led to a decrease in central nucleation, 
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we measured transcript abundance of genes involved in muscle regeneration.  Relative 
abundance of MyoG, MyoD, Mef2c, Myf5 and embryonic myosin heavy chain were similar 
between groups (Table 2).  Corresponding with a preservation of muscle fiber number was a 
44% (p≤0.05) reduction in immune cell infiltration when normalized to section area or a 62% 
(p≤0.05) reduction when normalized to muscle fiber number (Figure 2).  The reduction in 
immune cell infiltration was supported by a 31% (p≤0.05) reduction in Tnf transcript 
abundance in the diaphragms from the quercetin-enriched diet group compared to those in 
the control diet group (Figure 2).  Fibrotic area was decreased by 47% (p≤0.05) in 
diaphragms taken from quercetin-enriched diet group compared to mice in the control diet 
group (Figure 3).   
To better understand the mechanism underlying quercetin-mediated interruption of 
the disease process we assessed changes indicative of increased oxidative metabolism as well 
as changes associated with the slow/neuromuscular junction gene program.  Both of these are 
likely contributors to PGC-1α-mediated rescue of dystrophic muscle.  Transcript abundance 
of mitochondrial transcription factors Tfam, Tfb1m and Tfb2m were measured in the 
diaphragms of both treatment groups. Tfam transcript abundance increased 46% (p≤ 0.05) 
and Tfb1m abundance increased numerically by 28%, however, failed to reach significance 
(p≤ 0.08) (Figure 4) and Tfb2m did not differ between quercetin-treated and control group.  
Abundance of the mitochondrial encoded transcript CoxII (Mt-co2) was increased 55% (p≤ 
0.05) and cytochrome C (Cycs) exhibited a non-significant 45% numerical increase (p=0.07) 
with quercetin treatment.  UqcrcI, Errα, and Nrf1 did not differ between treatment groups 
(Figure 4).  With activation of the PGC-1α pathway a fast-to-slow myosin heavy chain shift 
is expected.  In the current study frequency of type I (slow), IIa, and IIb/x (fast) skeletal 
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muscle fiber types did not differ between groups (mdx-control: I -20.9 ± 4.5%, I/IIa -
2.2±0.6%, IIa-74±5.0%, and IIb/x-2.7± 0.9%;  mdx-quercetin: I-16.4±3.2% ,I/IIa-3.3±0.9%, 
IIa-75.9±3.5%, and IIb/x-4.4± 1.3%).  Further, transcript abundance of MhcI (Myh7), MhcIIa 
(Myh2), MhcIIx (Myh1), and MhcIIb (Myh4) did not differ between groups (Table 2).  
Associated with the slow/neuromuscular gene program is increased utrophin abundance.  We 
and others have previously measured increased utrophin gene and protein abundance 
following PGC-1α pathway activation (4, 6).  In this investigation we found that utrophin 
transcript (Table 2) and protein (Figure 5) abundance were similar between groups.  
 
Discussion 
While the cause of DMD is well known, effective therapies to treat this disease have 
been slow in reaching the patient population.  We have previously shown that up regulation 
of PGC-1α protein expression via viral gene transfer prevents disease onset and rescues 
dystrophic skeletal muscle from typical disease progression (4, 6).  In order to translate this 
experimental approach to an immediately available therapy we sought nutraceuticals that 
increase PGC-1α pathway activation and have a demonstrated safety profile.  In the current 
long-term feeding study we demonstrate that oral delivery of quercetin decreased indices of 
disease severity in diaphragms from mdx mice without obvious signs of toxicity.   
The current study demonstrates mdx mice feed a 0.2% quercetin-enriched diet had 
reduced muscle histopathology including preservation of muscle fiber number and decreased 
fibrosis.  Further, we also demonstrate that remaining fibers from mdx-quercetin diaphragms 
were in generally better health than those from mdx-control as central nucleation was 
decreased following consumption of the quercetin-enriched diet.  Consistent with these 
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observations, consumption of the quercetin-enriched diet was also associated with decreased 
inflammation.  It was beyond the scope of this investigation to determine the extent to which 
quercetin treatment decreased fibrosis and inflammation directly or indirectly by interfering 
with other aspects of disease progression and skeletal muscle injury.  The anti-inflammatory 
effect of quercetin treatment has been reported in the skeletal muscle of obese ob/ob mice 
(17).  
Guided by our previous findings in studies using gene transfer of PGC-1α we tested 
several hypotheses to better understand the mechanisms leading to quercetin-mediated 
interruption of the disease process.  Consistent with previous work, we found that quercetin 
treatment led to increased expression of oxidative genes.  This outcome is important as 
metabolic dysregulation (24, 25) and depleted ATP (25) content are characteristic of 
dystrophic muscle.  We did not detect evidence suggesting enhanced muscle regeneration, 
which we found in a previous study where PGC-1α gene transfer was used to rescue 
dystrophic muscle from disease progression (6).  Contrary to our hypothesis, we did not 
increase relative utrophin transcript or protein abundance.  Utrophin has been shown to 
substitute for the missing dystrophin protein in dystrophic skeletal muscle and restore 
resistance to contraction-induced injury (26, 27).  Additionally, utrophin has been repeatedly 
increased by PGC-1α gene transfer studies, however, supplementation with resveratrol, 
another dietary flavonoid, has, like quercetin, also failed to increase utrophin protein 
abundance (4, 9).  A recent report supports our hypothesis that PGC-1α pathway activation 
functions through multiple therapeutic avenues and is not solely utrophin-dependent (28).  
Muscle and body mass were also similar between groups, which is counter to expectations 
given that transgenic and virally-mediated PGC-1α overexpression led to reduced muscle 
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mass.  These findings suggest that, while dietary quercetin consumption did successfully 
decrease skeletal muscle injury, quercetin lead to only partial PGC-1α pathway activation.   
Careful scrutiny of several previous reports of oral quercetin administration indicates 
dose, method, and frequency of delivery may be key to more robustly activating the PGC-1α 
pathway.  In the current investigation quercetin was delivered in the food likely resulting in a 
consistent, though relatively small, increase in quercetin concentration for the duration of the 
project.  In contrast, studies using the gavage technique to deliver quercetin (14, 29) found 
increased PGC-1α pathway activation after one and six weeks, respectively, of a similar daily 
quercetin dose, likely causing a transient spike in bioavailable quercetin.  In order to robustly 
activate the PGC-1α pathway in skeletal muscle pulsatile spikes in plasma quercetin 
concentration may be needed rather than a prolonged low-level plasma quercetin 
concentration.  Another consideration is that the current investigation was carried out for six 
months where the former were considerably shorter in duration (days to weeks).  How the 
prolonged dosing regimen may affect efficacy is unclear, however, this remains an important 
consideration, as DMD patients would likely be treated with quercetin for an extended 
period.  Another possibility as to why the present results do not more closely match those of 
PGC-1α gene transfer studies is that PGC-1α protein content is decreased in dystrophic 
skeletal muscle compared with healthy skeletal muscle (30), thereby limiting the capacity for 
activation through deacetylation via Sirt1.  This biological limitation is overcome in gene 
transfer studies; however magnitude of change may also be important as it is unlikely that 
supplementation studies will increase PGC-1α content to that achieved in transgenic or gene 
transfer studies.  Finally, quercetin, without activation of other cellular processes, functions 
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as an antioxidant and anti-inflammatory, which have both been previously shown to decrease 
disease severity (16, 17). 
In conclusion, we demonstrate that dietary quercetin enrichment decreased disease 
indices in dystrophic skeletal muscle and appears to be a promising therapeutic avenue. The 
mechanism responsible for the observed improvements remains to be elucidated.  Increased 
expression of oxidative genes points toward activation of the PGC-1α pathway, however, a 
failure to increase utrophin transcript or protein abundance indicates this pathway was only 
partially activated.  We postulate that PGC-1α pathway activation can be maximized 
following careful study of dosing schemes.  Importantly, and consistent with the established 
safety profile of quercetin, animals receiving the quercetin-enriched diet did not exhibit signs 
consistent with toxicity.   
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Figures 
Figure1 
 
Figure 1. Body weight and food consumption during the six month study period in mdx mice. 
Data are means ± SEM. Food consumption did not differ between the control and quercetin 
diet treatment groups (A).  The increase in body mass during the six month study period did 
not differ between the control and quercetin diet (B) treatment groups.   
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Figure 2 
 
Figure 2.  Representative H&E stained diaphragm sections (200x).  Dystrophin-deficient 
mice were fed a control diet (A) or a diet containing 0.2% quercetin (B) for 6 months starting 
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at 3-mo of age.  Following 6 months of quercetin treatment muscle fibers per area were 
preserved (C), central nucleation decreased (D), number of infiltrating immune cells was 
reduced per area (E) and per muscle fiber (F).  In support of decreased immune cell 
infiltration is the decrease in TNF-α transcript abundance (G). Data are means ± SEM.  * 
indicates significantly different from control-fed animals (p≤0.05). 
 
Figure 3 
 
Figure 3.  Representative diaphragm images of fibronection IHC. mdx-contol diet (A) and 
mdx-quercetin (B) mice were either fed a control diet or a quercetin-enriched diet, 
respectively.  Fibrosis was significantly reduced in mdx-quercetin diaphragm compared to 
mdx-control (C). Data are means ± SEM. * indicates significantly different from control-diet 
animals (p≤0.05) 
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Figure 4 
 
Figure 4.  Oxidative genes expression.  mdx- quercetin mRNA abundance relative to mdx- 
control animals.  Data are means ± SEM. * indicates significantly different from control-fed 
animals (p≤0.05) ‡ indicates (p≤0.1) 
 
Figure 5 
 
Figure 5.  Representative images for utrophin IHC.  100x image of control diaphragm (A) 
and 100x image of quercetin supplemented diaphragm (B).  Utrophin abundance did not 
differ between mdx-control and mdx-quercetin treatments (C); Data are means ± SEM. 
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Table 1.  Primer sequences used for qPCR. 
Primer Name Primer Sequence 
Accession 
Number 
Length of 
Amplicon 
Tnf mouse For ccccaaagggatgagaagtt NM_013693.3 132 
Tnf mouse Rev cacttggtggtttgctacga 
  
    
Myog mouse For  tccagtacattgagcgccta NM_031189.2 238 
Myog mouse Rev  acgatggacgtaagggagtg 
  
    
Myod1 mouse For  agtgaatgaggccttcgaga NM_010866.2 222 
Myod1 mouse Rev  gcatctgagtcgccactgta 
  
    
Mef2c mouse For  cactagcactcatttatctc NM_001170537.1  178 
Mef2c mouse Rev  acagctgctcaagctgtcaa 
  
    
Myf5 mouse For  tgagggaacaggtggagaac NM_008656.5  198 
Myf5 mouse Rev  agctggacacggagctttta 
  
    
Myh3 mouse For  acgacaactcgtctcgcttt NM_001099635.1 205 
Myh3 mouse Rev ttggtcgtaatcagcagcag 
  
    
Myh7/MhcI mouse For  agatgaatgccgagctcact NM_080728.2  170 
Myh7/MhcI  mouse Rev ctcatccaaaccagccatct 
  
    
Myh2/MhcIIa mouse 
For  
gagcaaagatgcagggaaag NM_001039545.2 228 
Myh2/MhcIIa  mouse 
Rev taagggttgacggtgacaca   
 
 
  
Myh4/MhcIIb mouse 
For  
ggggctgtaccagaaatccg NM_010855.3  142 
Myh4/MhcIIb  mouse 
Rev 
cctgaagagagctgacacgg 
  
 
 
  
Myh1/MhcIIx mouse 
For  agaagctcctgggatccatt 
NM_030679.1 168 
Myh1/MhcIIx mouse 
Rev ctctcgccaagtaccctctg   
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Table 1 continued 
 
Utrn 3′ mouse For cgacaacatctggggaagat NM_011682.4 173 
Utrn 3′ mouse Rev gtgctctggccacatactga 
  
 
 
  
Utrn 5′ mouse For gtttgaggtgcttcctcagc NM_011682.4 203 
Utrn 5′ mouse Rev gcgatatctggtagctgtcc 
  
    
Esrra/ Errα mouse For  ccaggcttctcctcactgtc NM_007953.2  152 
Esrra/ Errα mouse Rev gccccctcttcatctaggac 
  
    
Cycs mouse For  ccaaatctccacggtctgtt NM_007808.4 192 
Cycs mouse Rev  gtctgccctttctcccttct 
  
    
Nrf1 mouse For  gcacctttggagaatgtggt NM_001164226.1  165 
Nrf1 mouse Rev  ctgagcctgggtcattttgt 
  
 
   
Tfam mouse For  ccaaaaagacctcgttcagc NM_009360.4 211 
Tfam mouse Rev  cttcagccatctgctcttcc 
  
    
Tfb1m mouse For  ctcctggacttgaggctgac NM_146074.1 170 
Tfb1m mouse Rev  aaccctgggataaagcgagt 
  
    
Tfb2m mouse For  tagagccgttgcctgattct NM_008249.4  194 
Tfb2m mouse Rev  taatgccccagtcaggattc 
  
    
Mt-co2/ CoxII mouse 
For  
acgaaatcaacaaccccgta AF378830.1 172 
Mt-co2/ CoxII mouse 
Rev  
ggcagaacgactcggttatc 
  
    
Uqcrc1 mouse For  gacaacgtgaccctccaagt NM_025407.2  249 
Uqcrc1 mouse Rev  actggtacataggcgcatcc 
  
     
   18S RT-primer gagctggaattaccgcggct NR_003278.3 
 18S mouse For gggaggtagtgacgaaaaataacaat NR_003278.3 101 
18S mouse Rev ttgccctccaatggatcct   
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Table 2. Genes that are similar between control and quercetin enriched diet. 
Fold change relative to mdx. 
Gene 
Abbreviation 
Fold 
Change 
p-
value 
Repair 
  
Myog 0.97 0.74 
Myod 1.02 0.95 
Mef2 1.31 0.22 
Myf5 1.16 0.21 
Mhc3 1.03 0.79 
   
Fiber type 
 
Mhc I 0.96 0.90 
MhcIIa 1.01 0.95 
MhcIIx 0.96 0.95 
MhcIIb 0.75 0.79 
Utrn 5′ 0.94 0.84 
Utrn 3′ 0.93 0.69 
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CHAPTER 5.  DYSTROPHIN INSUFFICIENCY CAUSES SELECTIVE MUSCLE 
HISTOPATHOLOGY AND LOSS OF DYSTROPHIN-GLYCOPROTEIN COMPLEX 
ASSEMBLY IN PIG SKELETAL MUSCLE
12
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Abstract 
The purpose of this investigation was to determine the extent to which dystrophin 
insufficiency caused histomorphological changes in a novel pig model of Becker muscular 
dystrophy.  In our procedures we used a combination of biochemical approaches including 
qPCR and western blots along with a histological analysis using standard and 
immunohistological measures.  We found that eight week old male affected pigs had a 70% 
reduction in dystrophin protein abundance in the diaphragm, psoas major and longissimus 
lumborum and a 5-fold increase in serum creatine kinase activity compared to healthy male 
littermates.  Dystrophin insufficiency in the diaphragm and the longissimus resulted in 
muscle histopathology with disorganized fibrosis that often co-localized with fatty 
infiltration, but not the psoas.  Affected animals also had an 80-85% reduction in α-
sarcoglycan localization in these muscles indicating compromised assembly of the dystrophin 
glycoprotein complex.  Controls used in this study were four healthy male littermates, as they 
are most closely related to the affected animals.  We concluded that pigs with insufficient 
dystrophin protein expression have a phenotype consistent with human dystrophinopathy 
patients.  Given that and their similarity in body size and physiology to humans we further 
conclude that this pig line is an appropriate translational model for dystrophinopathies. 
 
Key Words: Duchenne muscular dystrophy, DMD, Becker muscular dystrophy, BMD, 
animal model 
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Introduction 
Dystrophin mutations can result in substantial physical and locomotion deficits, 
leading to wheel chair confinement and early death due to respiratory and/or cardiac failure.  
The most severe form, Duchenne muscular dystrophy (DMD), is caused by a lack of 
dystrophin protein.  The generally less severe form, Becker muscular dystrophy (BMD), is 
caused by insufficient dystrophin abundance and/or expression of a partially functional gene 
product. 
Several existing dystrophin deficient animal models are currently used in the study of 
dystrophinopathies.  However, despite the many useful features of the different mouse and 
dog models a few significant drawbacks exist.  For example, the disease phenotype exhibited 
by mdx mice is much milder than that of human DMD patients (1, 2) in part due to increased 
abundance of utrophin, a dystrophin-like protein (3-5).  In order to mitigate this potential 
confounding variable, mdx/utrophin
-/-
 mice were developed (5).  While the disease phenotype 
is more severe in these mice, the double knock out approach allows for the possibility that 
muscle function and metabolism are affected independent of the dystrophin mutation.  
Additional dystrophin-deficient models with a secondary mutation have since been 
developed (5-7).  Regardless of mouse model, there is a poor correlation between 
effectiveness of therapies in mouse models to that observed in human patients (8) as scaling 
from a mouse to a human is challenging for a variety of reasons including, expense, safety, 
and differences in body size.   
In addition to mouse models, a golden retriever muscular dystrophy (GRMD) model 
has also been discovered and is the best characterized of identified dog models (9).  GRMD 
dogs have a phenotype that is more similar in severity and in selective muscle injury 
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compared to human patients than mdx mice (10, 11).  However, GRMD dogs have a high 
degree of phenotypic variability (12, 13), and as in the mdx mouse, limited adiposity is 
observed.  Finally, dystrophic dogs treated with corticosteroids exhibited a greater frequency 
of calcified necrotic fibers and impairment of some measures of muscle function (14), which 
is contrary to the beneficial effects of steroid use in human patients (15).  The objective of 
this project was to characterize the skeletal muscle phenotype of a recently discovered pig 
line with a spontaneously occurring substitution in exon 41 of the dystrophin gene causing an 
arginine to tryptophan amino acid change.  This substitution leads to decreased dystrophin 
abundance in skeletal and cardiac muscle (16).  In order to develop novel therapeutic 
strategies to treat dystrophinopathies there must be animal models that accurately recapitulate 
the disease.  Currently available models have been useful, however, their inherent limitations 
have hindered drug development and approval. The anatomy, physiology, and genetics of 
pigs are more similar to humans than the mouse or dog.  These similarities increase the 
likelihood of a more accurate recapitulation of the human disease and also mitigate 
challenges in drug scale up as pigs are of human size.  Pigs are currently being used widely 
for advancements in human health research (reviewed by (17)) so this suggestion is not 
unprecedented.  In this report we detail the early muscle response to dystrophin insufficiency 
in the diaphragm, psoas major, and longissimus lumborum. Our hope is that dystrophin 
insufficient pigs will aid in the development of therapeutic strategies by supplementing 
currently available animal models.  
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Material and Methods  
Animal Use.  All animal procedures were reviewed and approved by the U.S. Meat 
Animal Research Center Animal Care and Use Committee and procedures for handling pigs 
complied with those specified in the Guide for the Care and Use of Agricultural Animals in 
Agricultural Research and Teaching.  Animals were housed in 6.5 x 8 ft nursery pens by litter 
until eight weeks of age.  Affected pigs were identified by genotyping with a Sequenome 
MassArray system (San Diego, CA) (16).  At eight weeks of age four male affected pigs and 
four male healthy littermates were sacrificed by electrical stunning followed by 
exsanguination and approximately 5-g portions of the medial diaphragm, psoas major, and 
longissimus lumborum at the last rib were collected within 15 min of stunning.  Muscles 
were snap frozen in liquid nitrogen for biochemical analyses or frozen in isopentane or fixed 
in 10% buffered formalin for histological analyses.  Frozen samples were stored at -80°C 
until analyzed.  The diaphragm was chosen because it is used in respiration and is a primary 
cause of mortality in dystrophinopathy patients and therefore of importance for disease 
progression.  The psoas and longissimus were chosen because of their differing uses and 
composition of different fiber types.  Specifically, the psoas generally lightly used and is 
comprised largely of type I fibers, while the longissimus is generally used more frequently 
and is comprised primarily of type II fibers.  
Plasma Creatine Kinase Activity.  Plasma creatine phosphokinase (CK) was 
measured using a 2-part reagent system following the manufacturer’s instructions (Pointe 
Scientific Inc., Canton, MI) in a SpectraMax M5 microplate plate reader (Molecular Devices, 
Sunnyvale, CA). Twenty-five μL samples were measured in duplicate and the rate of NADH 
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formation was monitored at 340 nm at 37 °C.  Samples having greater than 2500 U/L were 
diluted in PBS and assayed again. 
mRNA Quantification.  Muscle samples were powdered with a dry ice chilled mortar 
and pestle.  Total RNA was extracted from approximately 50 mg of powdered muscle using 
Trizol (Invitrogen, Carlsbad,CA), following manufacturer instructions with minor 
modifications.  The RNA was then column purified (RNeasy Mini Kit, Qiagen, Valencia, 
CA) in order to minimize organic carryover.  On the column, and prior to RNA elution, 
DNase digestion (RNase free DNase set, Qiagen, Valencia, CA;) was used in order to 
prevent DNA contamination of the sample.  After quantification using a Nanodrop (Thermo 
Scientific, Waltham, MA), 1 µg of RNA was reverse-transcribed (QuantiTect Reverse 
Transcription Kit, Qiagen, Valencia, CA) following manufacturer instructions with the 
addition of reverse transcription primers for 18S ribosomal RNA.  The 18S rRNA does not 
contain a poly-A tail and addition of the 18S reverse transcription primers ensures the 18S 
rRNA can be converted into cDNA.  For qPCR, equal amounts of cDNA, corresponding to 
10 ng of reverse-transcribed mRNA, was loaded into each well.  To measure gene expression 
primer pairs (Table 1) were mixed together with a QuantiFast SYBR Green PCR kit (Qiagen, 
Valencia, CA) in a reaction volume of 12.5 µL and gene expression measured with a 
Mastercycler EP Realplex (Eppendorf, Hauppauge, NY). At the end of the PCR program, 
melting curves for all amplicons were inspected, in order to verify that a single product was 
amplified with each primer pair.  The pig genome has been sequenced and is well annotated 
(18) allowing construction of appropriate primer pairs.  All samples were measured in 
triplicate wells. 
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Protein Extraction.  About 500 mg of powdered muscle were added into a glass teflon 
dounce homogenizer with 0.7 mL extraction buffer (2% SDS, 10 mM Phosphate buffer, pH 
7).  Following ~20 strokes of the homogenizer the homogenizer was rinsed with 0.3 mL of 
extraction buffer, which was collected into the homogenized sample for a total dilution of 
2:1.  Samples were centrifuged at 1,500 x g for 15 min at room temperature to remove 
insoluble material.  Protein concentration was measured with the BCA kit (Pierce, Rockford, 
IL) at a 1:10 dilution in triplicate.  All samples were diluted to a protein concentration of 3.5 
µg/µL in loading buffer (62.5 mM TRIS pH 6.8, 2% SDS, 10% glycerol, 2.5% β-
mercaptoethanol and 0.002% Bromophenole blue) and heated to 95 °C for 5 min. 
Western Blot Analysis.  Thirty-five micrograms (10 μL) of protein were separated at 
60 V for 15 min followed by 1 h at 120 V in a 4-20% gradient polyacrylamide gel (Lonza, 
Rockland, ME).  Following separation the protein was transferred to a nitrocellulose 
membrane (GE Water and Process Technologies, Feasterfille-Trevose, PA,) at 90 V for 90 
min in the cold room.  For blots intended to detect dystrophin or utrophin, protein was 
separated using 6% gels coupled with a 4% stacking gel.  These separations were run at 30 V 
overnight and then continued as previously described with the exception that PVDF 
membrane (Millipore, Billerica, MA), rather than nitrocellulose membrane, was used.  In our 
hands PVDF performs better than nitrocellulose for detection of large proteins.  All 
membranes were stained with Ponceau S to verify equal loading and transfer.  Membranes 
were blocked for 30 min with 5% milk in Tris-buffered saline with 0.1% Tween 20 (TTBS).  
Membranes were subsequently incubated with primary antibody diluted in 1% milk in TTBS 
at 4 °C overnight as follows: dystrophin 1:500 (rabbit polyclonal, Abcam, Cambridge, MA, 
ab15277; amino acids 3661-3677), α-sarcoglycan 1:1000 (Novocastra, Newcastel, UK, NCL-
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L-a-SARC) and utrophin 1:250 (Hybridoma Bank University of Iowa, Iowa City, IA, 
MANCHO3(8A4) concentrate developed by Morris, G.E).  The next day membranes were 
washed 3 times for 10 min in TTBS and incubated in secondary antibody: donkey anti-rabbit 
IgG horseradish peroxidase linked 1:2000 (GE, Buckinghamshire, UK) or sheep anti-mouse 
IgG horseradish peroxidase linked 1:2000 (GE, Buckinghamshire, UK) for 1 h at room 
temperature, as appropriate.  Membranes were again washed 3 times for10 min with TTBS.  
After the last wash ECL (Millipore, Billerica, MA) was added to the membranes and emitted 
light captured with film.  To analyze the protein abundance the film was scanned, digitized, 
and band density was measured using Carestream molecular imaging software (Version 5.0, 
New Haven, CT). 
Histological Staining.  Fixed 5 µm muscle sections were deparaffinized and 
rehydrated by passing slides through three Citrisolv (Fisherbrand, King of Prussia, PA) baths 
and four ethanol baths with decreasing percentages of ethanol (100%, 100%, 95%, 80%).  
Hematoxylin and eosin (H&E) staining was performed according to standard techniques.  
Briefly, sections were incubated in Mayer’s Hematoxylin, rinsed with tap water, 
counterstained with 1% eosin, dehydrated and coverslips were applied.  To perform the 
trichrome stain rehydrated sections were incubated in Bouin’s solution overnight at room 
temperature.  The next day slides were thoroughly rinsed in tap water and stained with 
Weigert’s hematoxylin.  Slides were blued with tap water and stained with Biebrich scarlet.  
Excess stain was removed with distilled water before differentiating sections in a 
phosphotungstic/phoshomolybdic acid solution.  After differentiation slides were stained 
with Aniline blue.  Extra stain was washed off with distilled water and sections were 
differentiated in 1% acetic acid.  Finally, acetic acid was rinsed off with distilled water, and 
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sections were dehydrated and coverslips applied.  To assess muscle damage slides were 
coded and identifying information removed.  In a blinded fashion the same trained technician 
subjectively sorted the slides according to increasing damage. 
Immunohistochemistry.  Dystrophin expression and localization was measured using 
fixed sections.  Muscle sections (5 µm) were deparaffinized and antigen retrieval performed 
by heating for 20 min at 95-100 °C in Tris-EDTA buffer (10 mM Tris Base, 1 mM EDTA 
Solution, 0.05% Tween 20, pH 9.0).  After cooling to room temperature and two washes in 
PBS, slides were blocked with 5% BSA in PBS for 15 min at room temperature.  Following 
blocking, slides were incubated overnight at 4 °C with mouse monoclonal anti-dystrophin 
antibody (Sigma, Saint Louis, MO, D8168, amino acids 1400-1505) diluted 1:300 in 5% 
BSA.  After three washes with 0.05% Tween-20 in PBS sections were incubated with 
AlexaFluor 488-labeled goat anti-mouse IgG (1:100; Invitrogen, Carlsbad,CA) for 1 h at 
room temperature and then washed again.  Slides were mounted with Slowfade Gold 
Antifade Reagent with DAPI (Invitrogen, Carlsbad,CA).  Importantly, for all IHC targets, 
some sections were incubated without a primary antibody or without secondary antibody as 
negative controls.  
For detection of desmin, 10 µm frozen muscle sections were washed in PBS for 10 
min before blocking with 5% BSA in PBS at room temperature for 15 min.  Sections were 
incubated overnight at 4 °C with rabbit anti-desmin serum (1:100; a gift from Dr. Ted Huiatt, 
Iowa State University, Ames, IA).  The next day sections were washed 3 times with PBS and 
incubated with rhodamine conjugated donkey anti-rabbit IgG (1:100; Millipore, Temecula, 
CA) for 1 h at room temperature in the dark.  After the secondary incubation slides were 
washed 3 times with PBS and coverslips were mounted and sealed as above.  To assess 
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dystrophin-glycoprotein complex (DGC) stability in affected animals and healthy pigs IHC 
for α-sarcoglycan (Novocastra, Newcastle, UK) expression and localization was measured in 
combination with laminin (NeoMarkers, Fremont, CA).  Sections were treated as previously 
described and both primary antibodies were used at a concentration of 1:100.  Secondary 
goat anti-mouse fluorescein conjugated (Millipore, Temecula, CA) and goat anti-rabbit 
rhodamine conjugated IgG (Millipore, Temecula, CA) was used at a dilution of 1:100 for 1h 
at room temperature in the dark to detect α-sarcoglycan and laminin, respectively.  
For analysis of protein abundance following IHC two non-overlapping 200x pictures 
were randomly taken from each section with the appropriate filters.  For each protein, images 
were collected on the same day for each muscle under identical exposure conditions in 
random order and by a blinded technician.  Digital images were transferred to Openlab 
(Perkin Elmer, Waltham, MA) so that fluorescence intensity could be measured.  The density 
slice function was used to transform the image into a binary image such that pixels were 
identified as either above or below threshold intensity.  Threshold was determined by 
measuring pixel intensity of intracellular and extracellular areas as well as at several 
locations on the sarcolemma in various random sections.  All images were taken and 
processed under the same conditions.  To measure minimal Feret diameter the laminin 
images were converted into binary images as described above.  Images were then exported to 
the ImagePro software (MediaCybernetics, Rockville, MD) where the minimal Feret 
diameter tool was used to obtain the measurement. The measurements were exported to 
Excel where the data were binned and mean diameter and coefficient of variance calculated 
for each muscle. 
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For determination of fiber type differences in affected animals compared to healthy 
littermates IHC for slow myosin (A4.951) was performed in frozen sections in combination 
with laminin.  The A4.651 serum (Hybridoma Bank University of Iowa, Iowa City, IA, 
developed by Blau, H.M.) was used undiluted.  Type I MHC was detected using fluorescein 
conjugated goat anti-mouse IgG at 1:100 (Millipore, Temecula, CA) and laminin was 
detected as before.  Slides were imaged at 100x, which resulted in approximately 200-750 
cells/image.  For analyses, both the total number of cells/image and the number of positive 
staining cells/image were counted using Image J (19).  The cell counts from two 
images/section were pooled, resulting in approximately 500-1300 cells/section.  
Statistics.  All data are expressed as means ± SEM unless otherwise noted.  Data were 
compared using t-tests and significance was set at p ≤ 0.05.    
 
Results 
Dystrophin deficiency in pigs with an arginine to tryptophan (R1958W) substitution.  
Skeletal muscles from 8-week old male pigs with a missense mutation in the dystrophin gene 
were compared to healthy male littermates.  Dystrophin protein expression was decreased by 
70% in diaphragm, psoas, and longissimus collected from affected animals (tryptophan) 
compared to healthy littermates (arginine) (Figure 1a).  This decrease was confirmed by 70-
90% reduction in expression by immunohistochemistry in the diaphragm and the 
longissimus, but was not significantly different in the psoas (Figure 1b-c).  Notably, full 
length dystrophin protein was present in all muscles and it was evenly localized to the 
sarcolemma suggesting that these muscles are dystrophin insufficient as opposed to 
dystrophin deficient. 
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 To better understand the mechanism leading to decreased dystrophin protein 
accumulation we measured dystrophin gene expression (Figure 1 d-f, Table 1).  Gene 
expression was similar at the 5′ end of the gene, immediately upstream of the substitution in 
exon 41, across the substitution, and immediately downstream of the substitution in the 
diaphragm and psoas.  In the longissimus there was a 50% reduction in gene expression at all 
four locations.  Transcript abundance amplified by primers designed 3′ of the substitution 
was significantly lower in the diaphragm, psoas, and longissimus by 60, 45, and 70%, 
respectively, indicating decreased transcript stability.   
Dystrophin insufficiency is associated with muscle histophatology.  Dystrophin 
insufficiency was associated with a 5-fold increase in serum creatine kinase activity (Figure 
2a), which is consistent with other dystrophinopathy models and human BMD and DMD 
patients.  Additionally, affected and healthy animals could be distinguished from one another 
during histological evaluation (evaluator blind to the genotype of the animal) of the 
diaphragm and longissimus, but not the psoas.  Dystrophin insufficiency led to necrotic 
lesions in diaphragm and longissimus muscle, apparent in both H&E and trichrome images 
(Figure 2b).  Evident in these lesions was disorganized fibrosis and fatty infiltration that 
generally co-localized.  Immune cell infiltration was only occasionally present along with 
immune cell attack of skeletal muscle cells.  Gene expression indicating inflammation, 
including TNF, IL1B, and IL6, was similar between groups in all three muscles 
(Supplemental Table 1).  Notably rare in these muscles was the appearance of centralized 
nuclei.  Related, MYOD1 expression was similar between groups (Supplemental Table 1) 
for all muscles suggesting that satellite cell activation is not widespread.  While there were 
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necrotic lesions evident in the longissimus and diaphragm from affected animals there were 
also areas that appeared similar to healthy animals (Supplemental Figure 1). 
Mean fiber diameter (minimum Feret diameter) was similar between healthy and 
affected pigs across the three muscles (Supplemental Figure 2), however, the variance 
coefficient of fiber diameters was increased by approximately 20% in the diaphragm 
providing an objective measure of muscle injury (Figure 2c).  Variance coefficient of fiber 
diameter in the psoas and longissimus was similar between groups. 
Dystrophin insufficiency alters expression of DGC members, but not other membrane 
proteins.  In human patients and other animal models a lack of dystrophin or insufficient 
dystrophin expression leads to a collapse of the dystrophin glycoprotein complex (DGC).  
Gene expression of α-sarcoglycan (SGCA), α-dystrobrevin (DTNA), and NOS1 (also known 
as nNOS) was similar in healthy and affected animals for all three muscles (Supplemental 
Table 1).  Protein expression by Western blot, however, demonstrated a 50% reduction in 
SGCA abundance in all three muscles (Figure 3a).  Such discordant gene and protein 
expression for DGC components is consistent with other animal models as well as human 
DMD patients (20).  SGCA protein abundance was also measured by IHC and found to be 
decreased by 80-85% in the diaphragm and longissimus while expression was similar in the 
psoas (Figure 3b-c). 
 In addition to SGCA we also measured abundance and localization of several other 
membrane proteins.  Abundance and localization of laminin (Figure 3, Supplemental Figure 
3) and desmin (Supplemental Figure 4) were similar between healthy and affected animals 
for all three muscles.  Importantly, we found that utrophin gene expression (Supplemental 
Table 2) as well as protein expression was similar between healthy and affected pigs for all 
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three muscles (Figure 3d).  Hence, these muscles have a similar loss of expression and 
organization of the DGC as is observed in human patients and other animal models without 
observing compensatory utrophin expression as in the mouse model. 
 Because in other animal models and human patients dystrophinopathy is associated 
with a progressive type I shift we measured type I fiber distribution in these muscles.  
Surprisingly, at this early time point there was a 20% increase in type I fibers in the affected 
diaphragms compared to healthy muscle.  Fiber type distribution in the longissimus and 
psoas was similar between groups (Figure 4). 
 
Discussion 
 Because of inherent limitations in existing animal models of dystrophinopathy there 
has been great interest in establishing a novel large animal model of the disease.  A genetic 
line of pigs was recently discovered that was more susceptible to stress-mediated death.  A 
genome-wide association identified a defect in the dystrophin gene, which was associated 
with a reduction in dystrophin protein accumulation in skeletal muscle (16).  In this 
investigation we evaluated the expression and abundance of dystrophin and DGC 
components in diaphragm, psoas major, and longissimus lumborum muscle from healthy and 
affected 8 week male pigs.  For pigs, the use of the muscles examined in this study vary 
greatly in their function such that the diaphragm is used during respiration; the longissimus is 
a heavily used antigravity muscle and is involved in transitioning from laying to standing, 
during standing, in shifting weight from one leg to another, and in lying down; the psoas, a 
hip flexor, is only lightly used.  We found that in these muscles dystrophin protein 
accumulation was decreased in affected pigs as was expression of SGCA, a DGC component, 
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compared to healthy male littermates.  This was associated with muscle histopathology 
consisting of necrotic lesions, fatty infiltration, fibrosis, and increased fiber size variability in 
a muscle specific fashion.  Importantly, expression of utrophin, a protein that can substitute 
for the missing dystrophin protein, was similar between groups. 
At 8 weeks of age affected pigs had a 70% reduction of DMD in the diaphragm, 
psoas and longissimus compared to healthy littermates that resulted from a uniform reduction 
in dystrophin localization to the sarcolemma.  Because each muscle contained residual full 
length dystrophin these pigs are representative of a Becker phenotype, not Duchenne.  While 
the Leiden data base does not yet have record of a BMD-causing missense mutation at this 
precise location there are numerous documented instances of missense mutations leading to 
BMD (21-24).  To better understand the molecular cause of decreased dystrophin protein 
accumulation DMD gene expression was measured using primers against multiple sites along 
the DMD gene.  Gene expression in the longissimus was significantly reduced along the 
entire gene, while the diaphragm and the psoas only show a reduction at the 3′ end of the 
gene suggesting that the point mutation in the dystrophin gene makes the transcript less 
stable.  This 5′-3′ transcript imbalance also has been observed in BMD patients (25).  How a 
substitution in the amino acid sequence alters susceptibility to proteolysis is unknown.  To 
gain additional information regarding the probability of calpain degradation, using CaMPDB 
(26), we performed in silico digests of amino acids 1867 to 2097, which is inclusive of the 
amino acid substitution.  We found that the affected sequence was predicted to be more 
susceptible to calpain degradation than sequence from control animals.  Also, the vastly 
different amino acid properties of arginine and tryptophan likely contribute to aberrant 
protein folding or a resultant conformational change causing reduced protein stability (22).  
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Alternatively, altered electrostatic interactions in the rod domain may also destabilize the 
dystrophin protein (27).  These data suggest that dystrophin insufficiency results from 
decreased transcript stability and speculatively, increased protein degradation. 
 Like in other animal models (11, 28, 29) and human patients (30), failure to 
accumulate sufficient dystrophin protein leads to a systemic collapse of muscle stability 
resulting in a 4-fold increase in serum CK.  H&E and trichrome staining revealed injury in 
both the diaphragm and longissimus of affected animals, including fatty infiltration, fibrosis, 
and necrotic fibers.  A progressive increase in adiposity is a hallmark of dystrophinopathy in 
human patients (31) although is not present in the mdx mouse or the GRMD dog (1).  At this 
early time point, and similar to muscle from patients, we did not see accumulation of 
adipocytes and fibrosis throughout the entire muscle but rather co-localized within foci of 
necrosis.  Within these foci, fibrosis and infiltrating adiposity appeared disorganized in 
contrast to the high degree of organization found in healthy regions of muscles from affected 
animals and muscles from healthy animals. 
Fiber size variation is another indicator of muscle injury and 
degeneration/regeneration cycles where larger variance coefficients are indicative of disease 
in other animal models and dystrophinopathy patients (32).  Consistent with our subjective 
histological evaluation the objectively measured variance coefficients in fiber size 
distribution were significantly increased in diaphragm from affected pigs compared to 
healthy littermates.  Finally, dystrophic muscle undergoes a progressive type I shift as this 
fiber type is generally less susceptible to disease-related injury (33, 34).  While unexpected at 
this early time point, the frequency of type I fibers was increased in diaphragms from 
affected animals compared to healthy animals.  
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Despite being dystrophin insufficient like the diaphragm and longissimus, the psoas 
did not show signs of increased muscle histopathology as assessed through subjective 
histological evaluation or more objectively by fiber diameter variance.  The mechanism 
leading to preservation of the psoas is of potential therapeutic interest.  Like in the other 
muscles investigated, DGC abundance was decreased in psoas from affected animals, 
however, localization of DGC components was similar.  Hence, these data suggest that in the 
psoas a greater proportion of these proteins are resident at the sarcolemma than in the 
diaphragm or longissimus.  It is reasonable to suggest then that the similar DGC localization 
between the psoas from affected and health pigs protects the psoas from injury.  
Alternatively, the pattern of use of the psoas in pigs relative to the diaphragm and 
longissimus may differ resulting in less injury and subsequently allowing dystrophin 
accumulation at the sarcolemma.  If this were the case, it would suggest that increased use, 
such as during exercise, could hasten disease progression (35, 36).  Finally, the psoas is 
predominantly composed of type I fibers, which are generally more disease resistant than 
type II fibers, and may, therefore, offer protection from disease.  
The absence or reduction of DMD accumulation inhibits assembly of the DGC in 
dystrophic muscle (28-30).  In the affected diaphragm, longissimus, and psoas gene 
expression of SGCA, NOS1 and DTNA were similar to healthy littermates which is consistent 
with other animal models and human patients (20).  Dysregulation becomes apparent when 
evaluating protein accumulation and localization of these products.  Protein expression and 
localization of SGCA was decreased in the diaphragm and longissimus.  Surprisingly, the 
reduction in SGCA accumulation by Western blot measured in the psoas was not well 
matched with expression measured by IHC.  This was consistent, however, with dystrophin 
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measurement by IHC in this muscle.  Collectively, these observations indicate that in the 
diaphragm and longissimus DGC component proteins are being translated (albeit less than in 
healthy muscle) but are failing to integrate into the membrane.  Conversely, in the psoas, 
translated DGC components appear to integrate at an abundance that is similar to healthy 
muscle.  Apparent DGC fidelity is consistent with muscle injury such that at eight weeks of 
age muscle injury in the diaphragm and longissimus was apparent; however, the psoas was 
not distinguishable between diseased and healthy animals.   
Additionally, expression and localization of laminin, and desmin was similar between 
groups indicating that there is not a wholesale collapse of membrane structure.  Also, 
utrophin expression was similar between groups for all muscles eliminating one of the 
compensatory mechanisms, and hence, limitations, noted in other animal models.  
In total these data indicate that these pigs have muscle histopathology consistent with 
a dystrophinopathy.  That full length dystrophin is present at the membrane further implicates 
these pigs as a novel large animal model of Becker muscular dystrophy.  Given the genetic, 
anatomical, and physiological similarities between pigs and humans, and that these pigs 
recapitulate many hallmarks of disease, there is the promise that the BMD pig will result in a 
translational disease model capable of filling voids left by currently available 
dystrophinopathy models. 
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Figure 1. 
 
Figure 1.  Dystrophin protein abundance and localization.  Dystrophin was assayed in the 
diaphragm, psoas, and longissimus in muscles taken from healthy pigs and pigs containing an 
arginine to tryptophan (R1958W) polymorphism in exon 41 of DMD.  (A) By Western blot 
DMD protein abundance was decreased by 70% in muscles from diseased animals compared 
to muscles from healthy animals.  (B) Representative 400x images resulting from 
immunohistochemistry targeted to DMD.  (C)  Following fluorescence quantification, DMD 
abundance by IHC was significantly decreased in the diaphragm and longissimus (p<0.05), 
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however, failed to reach significance in the psoas in part because variability in the control 
animals was high and in part because the magnitude of change in the psoas was not as 
substantial as in the diaphragm and longissimus.  (D) Dystrophin transcript abundance at five 
locations along the DMD in the diaphragm.  (E) Dystrophin transcript abundance at five 
locations along the DMD in the psoas.  (F) Dystrophin transcript abundance at five locations 
along the DMD in the longissimus.  * indicates significantly different from corresponding 
control (p ≤ 0.05).  
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Figure 2.  Dystrophin insufficiency leads to muscle injury.  (A) Serum creatine kinase 
activity was increased 4-fold in affected pigs compared to healthy littermates.  (B) 
Representative 200x images of slides stained with H&E or trichrome.  In a blinded fashion, 
diaphragm sections and longissimus sections were successfully identified as either from 
healthy or affected pigs by the appearance of necrotic lesions, while affected and healthy 
psoas muscles were indistinguishable.  (C) The minimum Feret diameter was determined on 
500-1,200 cells/muscle for the diaphragm, psoas, and longissimus taken from healthy and 
affected pigs and the variance coefficient was calculated. Variance coefficient was increased 
in the diaphragm taken from affected animals compared to healthy animals but was similar in 
the longissimus and psoas.  * indicates significantly different from corresponding control (p 
≤ 0.05).           
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Figure 3.  Dystrophin insufficiency leads to a reduction in α-sarcoglycan abundance but not 
utrophin abundance.  (A) Representative Western blot of α-sarcoglycan indicating an 
approximate 50% reduction.  (B) Representative 400x images for immunohistochemistry of 
α-sarcoglycan.  (C) The fluorescent intensity was quantified and an 80-85% reduction was 
found in the diaphragm and the longissimus from affected animals while the psoas was 
similar between groups.  (D) Representative Western blot of utrophin and quantification. 
Utrophin was similar between groups * indicates significantly different from corresponding 
control (p ≤ 0.05).   
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Figure 4.  Dystrophin insufficiency alters fiber type distribution.  (A) Representative 200x 
image of immunohistochemistry for type I myosin heavy chain.  (B) Type I myosin heavy 
chain positive cells were increased 20% in affected diaphragms compared to diaphragms 
from healthy animals while the psoas and longissimus were similar between groups. * 
indicates significantly different from corresponding control (p ≤ 0.05).     
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Table 1.  Primer sequences used for qPCR.  
Primer Name Primer Sequence Accession 
Number 
Length of 
Amplicon 
DMD 5' pig For (Exon 9) CCTCGGTTCAAGAGCTATGC NM_001012408 128 
DMD 5' pig Rev (Exon 
10) 
TCCAACAATGAACTGCCAAA     
        
DMD 5' of SNP
1
 pig For 
(Exon 37) 
AGCAAACTTGATGGCAAACC NM_001012408 121 
DMD 5' of SNP pig Rev 
(Exon 38) 
AATGGAGGCCTTTCCAGTCT     
        
DMD across SNP pig For 
(Exon 40) 
TCAGTACAAGAGGCAGGCTG NM_001012408 330 
DMD across SNP pig Rev 
(Exon 42) 
GGCATGTCTTCAGTCATCAC     
        
DMD 3' of SNP pig For 
(Exon 41) 
AATTTGCTCACTTTCGAAGA NM_001012408 185 
DMD 3' of SNP pig Rev 
(Exon 42) 
GAGGTCAGGAGCATTGAGAA     
        
DMD 3' pig For (Exon 
62/63) 
CCACGAGACCCAAACAACTT NM_001012408 153 
DMD 3' pig Rev (Exon 
65) 
AGGCTCAAGAGATCCAAGCA     
TNF pig For GCCCTTCCACCAACGTTTTC NM_214022 158 
TNF pig Rev TCCCAGGTAGATGGGTTCGT     
        
IL1B pig For  AAGATAACACGCCCACCCTG NM_214055 293 
IL1B pig Rev TGTCAGCTTCGGGGTTCTTC     
        
IL6 pig For AGATGCCAAAGGTGATGCCA NM_001252429 363 
IL6 pig Rev  CTCAGGGTCTGGATCAGTGC     
        
MYOD1 pig For CTACAGCGGTGACTCAGACG  NM_001002824 121 
MYOD1 pig Rev GCTGTAATAGGTGCCGTCGT     
        
DTNA pig For ACTACCCACGGCAGTTTTTG XM_003356399 110 
DTNA pig Rev GCGTGTCCAAGAAACCATTT     
        
SGCA pig For AGGTCGAAAGGAAGGCGTAT NM_001144122 131 
SGCA pig Rev CATAGCAGGACAGCAGTGGA     
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NOS1 pig For GGAAAACAGTCTCCCACCAA XM_003132898 127 
NOS1 pig Rev ATCCTGTTCCCAATGTGCTC     
        
UTRN pig For GAACGGATCATTGCTGACCT XM_003121163 177 
UTRN pig Rev CCTGAGGAGTTTGGCTTCTG     
        
18S RT-primer GAGCTGGAATTACCGCGGCT     
18S pig For AAACGGCTACCACATCCAAG  NR_046261 141 
18S pig Rev TCGCGGAAGGATTTAAAGTG     
1
GeneBank dbSNP ss410758971 
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Supplemental Table 1.  Gene expression was similar for these genes between affected and 
healthy pigs.  Data shown as affected relative to healthy pigs. 
 
 Diaphragm Psoas Longissimus 
Gene fold-change p-value fold-change p-value fold-change p-value 
TNF 0.96 0.5 1.04 0.77 1.37 0.63 
IL1B 1.56 0.35 1.76 0.16 1.05 0.88 
IL6 1.64 0.47 1.64 0.17 3.45 0.26 
MYOD1 0.83 0.78 1.18 0.45 0.72 0.97 
DTNA 0.9 0.76 1.09 0.73 0.96 0.89 
SGCA 1.12 0.67 0.86 0.56 1.19 0.52 
NOS1 1.15 0.54 1.28 0.26 0.93 0.96 
UTRN 0.94 0.85 1.03 0.88 0.9 0.73 
TNF= tumor necrosis factor, IL1B= interleukin 1 beta, IL6= interleukin 6, MYOD1= 
myogenic differentiation 1, DTNA= alpha dystrobrevin, SGCA= alpha sarcoglycan, NOS1= 
(neuronal) nitric oxide synthase 1, UTRN= utrophin  
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CHAPTER 6.  SUMMARY AND CONCLUSIONS 
 
Duchenne muscular dystrophy is caused by dystrophin deficiency and leads to a host 
of secondary pathologies.  Independent correction of many of these contributing dysfunctions 
leads to beneficial changes to a variety of disease markers.  Recently, it was proposed that 
over expression of PGC-1α could correct multiple contributors of disease simultaneously 
resulting in decreased disease severity.  Previous studies analyzing benefits of PGC-1α 
focused on disease prevention (Selsby et al., 2012, Handschin et al., 2007), which is a crucial 
step in order to support a rational for PGC-1α over-expression as treatment for DMD.  
However, since patients are diagnoses because of their impaired muscle function, it is 
important to evaluate the potential of a therapy to rescue dystrophic muscle from further 
disease decline.   
 In the first study (Chapter 2) PGC-1α was administered to the hind limb of mdx mice 
during the initial bout of necrosis.  Even in actively degenerating muscle PGC-1α over-
expression improved histopathology and muscle function.  Further, we were able to identified 
novel ways by which PGC-1α conferred beneficial effects to skeletal muscle.  As 
hypothesized, PGC-1α led to the activation of a slow oxidative muscle program, increased 
utrophin protein abundance, and mitochondrial biogenesis.  Increased PGC-1α also improved 
muscle regeneration and autophagy.  In the next study (Chapter 3) we wanted to extend these 
observations and increase the clinical relevance of this work.  To that end, PGC-1α gene was 
transferred in muscle with repeated cycles of degeneration/regeneration.  In this environment 
PGC-1α over expression restored muscle function but did not improve histopathology.  
Further, we did not detect activation of any of the previously identified pathways.  It seems 
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likely that the intracellular environments of acute muscle injury and prolonged muscle injury 
are sufficiency different to alter the cellular response to this intervention.  Together these 
studies validate that PGC-1α is a good therapeutic target for DMD and that this approach can 
be used to rescue declining muscle, however early intervention appears better at mitigating 
the disease phenotype. 
 While gene therapy approaches hold tremendous promise for the future we also wanted to 
identify an approach we could use immediately to increase PGC-1α pathway activation.  To 
that end, we investigated the potential of the nutraceutical, quercetin, a Sirt1/PGC-1α 
activator, to decrease disease severity using a rescue paradigm.  Quercetin is safe for human 
consumption and orally available making this approach translatable to the DMD patient 
population.  Quercetin was able to rescue histopathology of dystrophic muscle and partially 
activate the PGC-1α pathway.  We only observed an increase in oxidative genes but not in 
utrophin protein abundance.  Nevertheless, quercetin seems to be a promising strategy to 
increase PGC-1α pathway activity and importantly, decrease disease severity.   
 Finally, while existing mouse models have contributed to our understanding of disease 
mechanisms their contribution to the development of novel therapeutics has been relatively 
small.  This is largely because of limitations inherent in the existing models (size, response to 
steroids, etc.).  In order to move new strategies successfully to clinical trials a new animal 
model is needed.  A translational model needs to be close in size and physiology to humans.  
Also, consistent phenotypic expression would be of value.  As a first step to validating a new 
pig model for BMD we assessed histopathology and changes to DGC assembly in 8wk old 
pigs with a spontaneous mutation the dystrophin gene.  From a histopathological perspective 
these animals recapitulate many aspects of human disease including foci of necrosis, a loss of 
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the DGC, and increased fiber diameter variability.  Therefor these it is reasonable to conclude 
that these pigs are a good preclinical model for BMD.  
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